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Abstract 
Despite a rise in the number of studies looking at the relationship of psychosocial factors 
(coping style, personality type, and social support) on HIV/AIDS severity, there remains a lack 
of conclusive answers about the specific association between these factors. This study used a 
meta-analytic method of analysis to address these issues in the post anti-retroviral treatment 
modality world. A systematic search of major psychology and medical computerized databases 
led to 110 studies used in the meta-analysis. Social support was found to have the strongest 
relationship with HIV progression. Structural social support had greater protective effect on HIV 
progression than functional social support. A significant relationship between coping type and 
HIV severity was found, with a greater protective benefit seen in studies that utilized CD4 count 
as the outcome variable. Positive coping had a beneficial effect on HIV progression while 
passive and negative coping had a detrimental effect on disease progression. Among studies of 
personality, a weak relationship was found between personality type and HIV severity. In 
conclusion, the meta-analytical review found significant associations between psychosocial 
factors and HIV severity that could be used to refine individual treatment plans for people living 
with HIV/AIDS. 
 Keywords: Psychoneuroimmunology, HIV/AIDS, social support, coping, personality 
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The Association of Psychosocial Factors on HIV/AIDS Disease Progression 
 
There are approximately 34 million individuals living with HIV and 30 million people 
who have died of AIDS-related causes since the first case was found (UNAIDS, 2012). Despite 
the advancements in medical technology that help treat the disease, only 8 million individuals 
living with HIV have access to antiretroviral therapy (ARV), leaving a large amount of 
individuals without medication. Thus, it is of utmost importance to identify the psychosocial 
factors that affect disease progression so individuals can better their health outcomes through a 
complementary model of healing.  
 The purpose of this thesis was to examine the results of previous empirical studies that 
analyzed the association between psychosocial factors and HIV/AIDS progression using a meta-
analytic approach.  Specifically this paper examined the correlations of the psychosocial factors 
of personality (Five-Factor Model: neuroticism, openness to engagement, extraversion, 
agreeableness, and conscientiousness), coping type (positive, passive, or negative), and social 
support type (functional or structural) on the dependent variables of CD4 count and viral load. 
The first aim identified the nature of the relationship between the five-factor model of 
personality and the progression of HIV as measured by CD4 count and viral load. The second 
aim of the study, analyzed the relationship between HIV-seropositive individuals’ coping type 
and progression of HIV as measured by CD4 count and viral load. The third aim of the study 
examined the relationship of type of social support and progression of HIV as measured by CD4 
count and viral load. The following sections provided a composite view of the psychosocial 
factors and discussed how these variables relate to health and immunity of HIV-seropositive 
individuals. The results from examining the nature of the associations of the psychosocial factors 
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on progression in this study have a tremendous impact on comprehensive mind-body 
individualized treatment plans for HIV+ individuals in order to improve their survival and well-
being. 
Human immunodeficiency virus virology 
Human immunodeficiency virus (HIV), the clinical precursor to acquired immunodeficiency 
syndrome (AIDS), is disease affecting the immune system of infected individuals that makes the 
individual more vulnerable to potentially fatal opportunistic infections and cancer (Basic 
Information about HIV and AIDS, 2012). AIDS is clinically defined by either a CD4+ T cell 
count of below 200 cells per µL or the presence of diseases associated with the syndrome such as 
pneumocystis pneumonia, esophageal candidiasis, Kaposi’s sarcoma, and AIDS related dementia 
(AIDS-PubMed Health, 2012). The virus is potentially transmitted by three main ways: sexual 
contact with an infected individual, exposure to infected fluids, and vertical transmission (in 
order of frequency) (Basic Information about HIV and AIDS, 2012). 
 HIV functions through infection of the immune system, specifically the CD4+ T cells, 
macrophages, and dendritic cells (Alimonti, Ball, & Fowke, 2003). As viral replication occurs 
more rapidly CD4+ T cell counts of the infected individual drop, a marker of disease progression 
and severity. The normal CD4 count of a HIV-seronegative individual is 1,000 cells as opposed 
to that of 200 cells or less of an individual with AIDS (Osmond, 1998). In the current study the 
construct of CD4 counts was used as the dependent variable in measurement of HIV progression.  
Viral load is another measurement used to measure the severity of the virus. It is a calculation of 
the amount RNA copies per milliliter of blood plasma. Although, CD4 counts and viral load are 
similar concepts in assessing progression and severity of HIV/AIDS they are useful in different 
aspects of treatment. CD4 counts are measures of immunocompromise useful in determine risk 
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for opportunistic infections, stage of disease, prognosis, and whether or not to being 
antiretroviral therapy (ART). Viral load measurement is more useful in determine the rate of 
disease progression and for ART (CD4 Monitoring and Viral Load Testing, 2011). A low CD4 
count combined with a high viral load is indicative of progression, severity, and an increased risk 
of contracting opportunistic diseases. In the current study the construct of viral load was used as 
the dependent variable in measurement of HIV progression.   
Psychoneuroimmunology  
In the last few decades etiologies of disease have changed from purely biological to a 
comprehensive model, marking the beginning of the field of psychoneuroimmunology. The field 
of psychoneuroimmunology seeks to take an interdisciplinary approach to looking at the 
interaction between the nervous and immune systems with the psychological. One of the main 
theories of the field is the Engel’s biopsychosocial model. This model proposes that the etiology 
of disease is based on a reciprocal determinism triad of biology, social factors, and psychology 
(Engel, 1977). This means that one’s emotions, cognitions, behaviors, interpersonal relations, 
and environment affect the severity and progression of a disease as opposed to solely one’s 
biology. Another important theory to the field is the stress immunity health model (SIH), which 
seeks to understand how stress impacts one’s immunity and thus lead to negative health 
consequences (Keller, Shiflett, Schleifer, & Bartlett, 1994). Biologically, glucocorticoids such 
cortisol are released in response to stress acting as an immunosuppressant and increase HIV virus 
reproduction (Cupps & Fauci, 1982). 
Stress as understood with the SIH model has a direct link to adverse health consequences. 
Since, stress is increased or decreased by personality type, coping style, and/or social support it 
is important to analyze these mediating factors as well. Stress is difficult to operationalize 
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however Taylor defines the construct as “a negative emotional-experience accompanied by 
predictable biochemical, physiological, cognitive, and behavioral changes that are directed 
toward altering the stressful event or accommodating to its effects” (Taylor, 1999, p. 198). This 
wide definition includes the environmental variables and individual physiological events that 
include personality and social supports. The level of stress can be measured psychologically 
through stress scales or through physiological measures of blood pressure or galvanic skin 
response. Although, stress is not being directly analyzed in this meta-analysis it is indirectly 
associated with each of the psychosocial factors measured. For example, an association exists 
between the five-factor model personality trait of openness to experience and stress regulation. A 
study of 73 individuals analyzed the impact that openness had on regulation of an acute 
laboratory stressor. Researchers found that individuals who scored high on openness had greater 
stress resilience and less likely to develop adverse health effects such as increase in blood 
pressure activity or negative affect. Individuals who scored low on openness were found to be 
more vulnerable to the effects of stress such as poor sleep quality, increase in respiratory sinus 
arrhythmia and increase in blood pressure (Williams, Rau, Cribbet, & Gunn, 2009). Overall, it is 
important to note the way in which stress negatively impacts the health in order to understand the 
results of this study. Stress exists as a mediating variable for the three psychosocial factors 
analyzed in this study. Since it does exist as mediating variable this is important in the 
interpretation of the results. 
Chronic Disease 
Chronic diseases have a biological and psychological effect on the individual. Chronic 
diseases are defined as being persistent or having long-lasting effects for more than three months 
(Chronic Disease, 2012). The most common examples are arthritis, cancer, cardiovascular 
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disease, diabetes, and HIV/AIDS. Chronic disease has psychological effects with diagnosis, 
symptoms, medication adherence, stigma and long-term effects requiring adjustment in many 
different aspects of one’s life. Research has identified five categories of adjustment to chronic 
disease: mastery of disease related adaptive tasks, preservation of functional status, quality of 
life, low negative affect, and psychological disorders (Stanton, Collins, Sworowski, 2001). 
Positive adjustment within these five categories for the purpose of this study would indicate high 
levels of social support, positive coping, and thus slower HIV/AIDS disease progression. 
 Stress plays an important factor in the etiology, prognosis, and severity of chronic 
disease. The effect of stressors on infectious disease outcomes has been tested through 
vaccination responses, viral challenge, and reactivation of latent viruses. In Cohen’s viral 
challenge research, 420 healthy individuals were inoculated with a type of cold virus under 
controlled conditions and then were measured daily for infections symptoms. Cohen found that 
higher stress (measured through amount of stressful life events, perceived stress, and negative 
affect) predicted greater susceptibility to the virus, increase in symptoms, and lower immune 
system functioning (Cohen, Tyrrell, & Smith, 1991). A similar association between lower 
immune system functioning and higher amount of life stressors was found in a study of 68 
patients with malignant melanoma (Fawzy et al., 1993). Cancer patients with greater self-
reported severe life stressors were associated with a greater chance of relapsing. In a follow-up 
study patients participated in a six-week structured psychiatric group intervention focusing on 
stress coping interventions. The researchers found that the adverse health outcomes caused by 
severe life stressors seen in the previous study were not present but rather the patients had 
improved survival rates and greater immune functioning. Studies looking at the effect of stress 
on immunological functioning of chronically ill patients can be applied to HIV-seropositive 
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individuals. For the purpose of this study stress is not a distinct independent variable but rather 
implicitly tied to the independent variables of personality, coping type, and social support. 
Five-Factor Model of Personality 
 Personality is defined as set of unique characteristics an individual possesses that 
influences one’s behaviors, emotions, motivations, and cognitions (Schacter, Gilbert, & Wegner, 
2010). The specific operationalized definition of personality used in this study is the big five 
personality traits measured by the revised NEO Personality Inventory (NEO PI-R). The five 
personality traits measured are agreeableness, conscientiousness, extraversion, neuroticism, and 
openness to experience, with six facets as part of each trait (Costa & McCrae, 1992). Costa and 
McCrae’s Five Factor Model of personality was chosen in this study as it is one of the leading 
approaches to measuring personality. The NEO PI-R is high in validity in comparison to the 
MBTI, MMPI, and Self-Directed Search (Costa & McCrae, 1992). The internal consistency of 
the NEO PI-R for each of the domains ranges from a Cronbach’s alpha score from .89 to .93 
(McCrae & Costa, 2010). The test retest reliability of the NEO PI-R over a six year period is N = 
.83, E = .82, O = .83, A = .63, and C = .79 (McCrae & Costa, 2010). 
 Neuroticism. According to the Five-Factor Model neuroticism is the tendency to 
negative emotions, such depression, anxiety, or anger (Matthews & Deary, 1998). The facets on 
the NEO PI-R are anxiety, hostility, depression, self-consciousness, impulsiveness, and 
vulnerability to stress. Individuals who are high in neuroticism are more vulnerable to stress and 
have a lower tolerance for stress (Norris, Larsen, & Cacioppos, 2007). Individuals high in 
neuroticism are more likely to be emotionally reactive, interpret their environment as 
threatening, and be more likely to develop depression (Matthews & Deary, 1998). All of the 
characteristics of an individual high in neuroticism point to the individual perceiving more stress, 
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which has adverse effects on one’s health. One study found high neuroticism was positively 
associated with perceive stress and negative emotion in response to an acute stressor (Penley & 
Tomaka, 2002). 
However there are mixed findings in terms of a conclusive connection between 
neuroticism and negative health outcomes (Ironson et al., 2008). A link between high 
neuroticism and poorer health has been found with chronic renal insufficiency (Christensen et 
al., 2002), mortality (Wilson et al., 2004), and with cancer and coronary heart disease (Eysenck, 
1993). However, some studies have found a protective effect with high neuroticism in terms of 
mortality (Weiss & Costa, 2005) and myocardial infection (Korten et al., 1999).  
Similarly, mixed findings have been found regarding the association of neuroticism and 
HIV progression. In a study of 104 HIV-seropositive individuals found that neuroticism scores 
from the NEO-PI-R were not significantly associated with a change in viral load over time but 
there was a significant association with a faster decrease of CD4 cells (Ironson et al., 2008). In 
the same study lower neuroticism (N) was found to be protective and slow progression of the 
disease when combined with high extraversion (E), openness (O), or conscientiousness (C). 
Another study looked at the effect of neuroticism on amount of negative disease symptoms 
reported. The study found that the HIV-seropositive individuals who scored high in neuroticism 
were more likely to complain and report disease symptoms. However the somatic complaints did 
not translate to significant measurable differences in severity or progression, as measured 
through CD4 counts and viral load (Johnson & Neilands, 2007). One hypothesis why 
neuroticism has not been conclusively associated with negative health outcomes is the symptom 
perception hypothesis. This hypothesis states that individuals who are high in neuroticism are 
more likely to have somatic complaints but this does not necessarily reflect actual negative 
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health or increased mortality (Costa, 1987). Thus it is important to note the methodology of 
studies of neuroticisms and HIV severity and progression whether the measurement of severity 
of what is patient reported or not. Neuroticism is hypothesized to have a weak negative 
relationship to the outcome variables. This was predicted due to the weak association of 
neuroticism and HIV progression found in the literature review and the symptom perception 
hypothesis. As the level of neuroticism increased a faster disease progression was predicted as 
indicated by higher viral loads and lower CD4 counts. 
Extraversion. According to the Five-Factor Model extraversion is characterized by 
tendency towards the company of others, assertiveness, and positive emotion. In contrast, 
introverts are marked by their need for less social engagement and activity, deliberate choices, 
and quietness. A moderate score would be an individual who is energetic but distant or lethargic 
but friendly (McCrae et al., 1986). The facets of extraversion on the NEO PI-R are warmth, 
gregariousness, assertiveness, activity, excitement seeking, and positive emotion. 
 The trait of extraversion has been found to be protective against negative health 
outcomes, although many studies have not found a significant association. Individuals who were 
high in extraversion rated their health as higher than those low in extraversion (Williams, 
O’Brien & Colder, 2004). With extraversion’s association to mortality, only two studies have 
found a significant protective effect (Shipley, Weiss, Der, Taylor, & Deary, 2007). Low 
extraversion scores have been seen with individuals with chronic diseases such as chronic fatigue 
(Nater, Jones, Lin, Maloney, Reeves, & Heim, 2010), cancer patients (Cardenal, Cerezo, 
Martinez, Ortiz-Tallo, & Blanca, 2012), and renal failure (Kidachi, Kikuchi, Nishizawa, Hirum, 
& Kaneko, 2007).  
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 Although research regarding the trait extraversion and health outcomes may be mixed, 
the trait may play more of a significant role in HIV+ individual’s disease progression. This may 
be explained by the direct connection between extraversion and social support. In a study of 104 
HIV-seropositive individuals the role of the extraversion and its facets was examined in its 
relation to changes in CD4 and viral load counts. Ironson found that extraversion’s facets of 
assertiveness, positive emotion, and gregariousness were significantly associated with slower 
disease progression (Ironson et al., 2008). In a study of 96 individuals examining the prospective 
association of affect on HIV disease progression looked specifically at the facet of assertiveness. 
The researchers found that individuals with high scores on assertiveness are more likely to seek 
the support they need thus leading to more positive health outcomes (Leserman et al., 2002). 
Moskowitz analyzed the association of positive affect on HIV disease progression among 407 
HIV+ San Francisco men. He found that positive emotions were significantly linked to slower 
disease progression (Moskowitz, 2003). Research of 177 HIV+ patients over a period of two 
years found that individuals who scored low in optimism loose CD4 cells 1.55 times faster than 
individuals who score on scales of optimism (Ironson et al., 2005). Similarly, in a study looking 
at the role of dispositional optimism and HIV progression in a cohort of 412 HIV+ individuals 
low scores of optimism were correlated to a higher viral load and thus faster disease progression 
(Milam, Richardson, Marks, Kemper, & McCuthchan, 2004). Optimists are more likely to adopt 
positive coping strategies than passive or negative styles (Ironson et al., 2005). Extroverted 
individuals are more likely to experience social support as they have a larger social network than 
introverted individuals. Larger network sizes predict slower disease progression over a five-year 
period (Patterson et al., 1996). Positive affect, an aspect of positive coping, predicts lower 
mortality in a study of 407 HIV-seropositive men over a three-year study period (Moskowitz, 
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2003). The trait of extraversion is interlinked to the two other psychosocial factors measured, 
coping style and social support, in relation to HIV/AIDS progression and thus was hypothesized 
to be one of the strongest associations. The association of extraversion on both of the outcome 
measurements was predicted to be greater than the association between the outcome variables 
and the other personality traits (neuroticism, openness to experience, agreeableness, and 
conscientiousness). As the level of extraversion increased a slower progression was predicted as 
indicated by lower viral loads and higher CD4 counts. 
 Openness to Experience. According to the Five-Factor Model openness to experience 
characterizes individuals as sensation seeking and willingly appreciative of their perceived 
experiences for themselves. The openness facets on the NEO-PR-I are fantasy, aesthetics, 
feelings, actions, ideas, and values. Individuals with high scores of openness to experience are 
more likely to have an active imagination, high curiosity, attentive to inner emotions, and 
preference for variety (McCrae & John, 1992). An individual who scores low in openness are 
more likely to be conventional, traditional in perspective and behavior, favor routine, and 
traditional religiosity (McCrae & John, 1992).  
 There are mixed findings regarding the correlation between openness and health 
outcomes. Openness has been found to positively affect stress responses through predicting 
lower negative affect and lower cortisol response (Schneider, Rench, Lyons, & Riffle, 2012). 
Another study conducted in a cohort of 97 undergraduates looked at the association of NEO-PI-R 
personality traits when experiencing the acute stressor of public speaking. The study found that 
individuals who scored high on the NEO-PI-R’s openness scale reported lower perceived amount 
of stress in response to acute stressor task (Penley & Tomaka, 2002). A number of studies have 
found a significant relationship between negative self-rated health and low scores on openness 
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trait on the NEO-PI-R (Goodwin & Engstrom, 2002). However, high scores in openness may 
still be slightly negative in terms of social support and coping; these individuals are more likely 
to be highly sensitive to feelings and may have difficulties relating to others (McCrae, 1993). In 
terms of the association between chronic disease severity and openness there has been very few 
studies conducted. A study of 300 asthmatic patients analyzed the relationship between 
personality traits and the severity and duration of the disease. They found that the patients who 
had high scores on the openness scale also experienced a less severe and shorter version of the 
disease than those who had low score openness scores (Fernandes et al., 2005). Furthermore, the 
average asthmatic individual in the study had lower openness scores than the average score for 
individuals in the general population. This may be due to the finding that individuals who are 
low in openness have greater aggregate medical illnesses than those high in openness (Chapman, 
Lyness, & Duberstein, 2007). Research regarding the association of low scores openness and 
morbidity is weak. In a study of 977 patients with significant coronary artery disease researchers 
analyzed if certain facets of openness on the NEO-PI-R predicted mortality. They found a 
predictive relationship with mortality with individuals who had low scores in the facets of feeling 
and actions (Jonassaint et al., 2007). In looking at the findings of correlations between openness 
and health outcomes it is important to recognize the potential confound of education. A slightly 
significant association exists between high scores on the scale of openness and greater cognitive 
ability and academic performance (Steenland, Henley, & Thun, 2002). A study by the American 
Cancer Society of two million people looked at the association of educational status on morality. 
The authors found a direct association between lower educational status and negative health 
outcomes and mortality. Men who were considered high in educational status lived 4.8 years 
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longer and women lived 2.7 years longer than members of the cohort who were considered lower 
in educational status.  
 Although there are lack of studies regarding the association of openness and HIV 
progression, the largest study analyzing this association has found a significant association with 
slower disease progression as measured by CD4 counts and viral load (Ironson et al., 2008). A 
study of 104 HIV-seropositive patients examined the role of the big five personality traits on 
their change of CD4 and viral load. They found that patients who scored low on the NEO-PI-R’s 
openness domain had a viral load more than three times greater than patients who scored higher 
on the openness scale. Furthermore, individuals with low openness scores also had a 
significantly decreased CD4 count compared to individuals higher in openness over the four-year 
study period. (Ironson et al., 2008). Studies have shown that the relationship between openness 
and progression to be weaker than with the other five factor model of personality traits and thus 
it was hypothesized to have a weaker association in this study. In the present study, as the level 
of openness was predicted to increase a non-significant effect on HIV disease progression was 
expected as measured by the CD4 count and viral load outcome measurements. 
 Agreeableness. According to the Five-Factor Model agreeableness is the tendency to be 
sympathetic, cooperative, kind, warm, and considerate (Thompson, 2008). The facets on the 
NEO PI-R are trust, straightforwardness, altruism, compliance, modesty, and tender-mindedness 
(Costa & McCrae, 1992).  Individuals who are low in agreeableness are less concerned with 
others’ wellbeing, low in empathy, and have a tendency to be manipulative and skeptical in 
social situations (Graziano & Eisenberg, 1997). 
The trait of agreeableness is extremely important to psychological wellbeing of an 
individual as well as physical health. Agreeableness is considered a predictor of health behavior 
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(Botth-Kewley & Vickers, 1994), which can be seen with its significant negative association 
with chronic stress (Ebstrup et al., 2011) and its protective effect on mortality with the general 
population (Weiss & Costa, 2005) and individuals with chronic diseases (Izdebski, 2007). 
Research has shown that agreeableness is associated with faster disease progression with 
hypertension (Sutin et al., 2010), ALS (Krampe et al., 2008), and breast cancer (Fisher, 1995). 
There are mixed findings regarding the correlation between agreeableness and HIV 
progression. A study of 104 HIV-seropositive patients examined the role of the big five 
personality traits on their change of CD4 and viral load. They found that patient’s scores on 
agreeableness were not significantly related to change in viral load or CD4 count over time 
(Ironson et al., 2008). However in a study looking at the relationship between the five-factor 
model and immune system functioning in a 66 HIV+ African American females a different result 
was found. Using CD4 count as a measure of immunity, they found that agreeableness was found 
to be the most significant predictor of CD4 change (Millner, 1998). This significant result can be 
largely explained by high significance of the altruism facet of agreeableness in its positive 
correlation with CD4 count. Further research needs to be conducted regarding the association of 
agreeableness and HIV progression as studies have found either to be the most important 
personality trait predictor or completely insignificant. Agreeableness was hypothesized to have 
one of the most significant associations among the personality types in regards to disease 
progression based on the literature review. It was hypothesized that as the level of agreeableness 
increased there would be slower disease progression as indicated by lower viral loads and higher 
CD4 counts.  
 Conscientiousness. According to the Five-Factor Model conscientiousness measures 
one’s control, regulation, and direction of impulses (Costa & McCrae, 1992). The facets on the 
PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION 17
NEO-PI-R are competence, order, dutifulness, achievement striving, self-discipline, and 
deliberation. An individual high in conscientiousness would be more likely to be exhibit self-
control, determined, punctual, reliable, purposeful, and strong willed (Costa & McCrae, 1992). 
Individuals who score low in conscientiousness are less motivated in task completion, less driven 
by success, and less goal-orientated.  
Conscientiousness is considered the most important personality predictor of health 
(Christensen et al., 2002). Conscientiousness is considered the most significant psychological 
predictor of longevity due to its association with the nine leading causes of mortality (alcohol 
use, obesity, drug use, exercise, risky sexual behavior, risky driving, violence, suicide, and 
tobacco use) (Friedman & Martin, 2011). Individuals low in conscientiousness during chronic 
stress experience greater increase in cortisol making them more susceptible to illness than those 
high in conscientiousness (Savic, Knezevic, Damjanovic, Spiric, & Matic, 2012). Individuals 
with chronic physical diseases ranging from tuberculosis to diabetes have significantly lower 
levels of conscientiousness (Goodwin & Friedman, 2006). 
Research has shown that high conscientiousness causes slower HIV disease progression 
over time. In a study of 104 HIV-seropositive individuals looking at the role of personality as 
measured by the NEO-PI-R and HIV disease progression, high scores on conscientiousness were 
associated with slower disease progression. Over the four-year study period, individuals who 
scored lowed on the conscientiousness scale experienced an increase in viral load of 1.62 times 
greater than individuals high in conscientiousness (Ironson et al., 2008). This study found that 
the facet of achievement striving had the strongest association with HIV progression out of all 
the facets of conscientiousness (Ironson et al., 2008). Another longitudinal study conducted over 
a one-year period with 119 HIV-seropositive patients found that conscientiousness predicts 
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disease progression. Individuals who had lower scores on the conscientiousness scale 
experienced a yearly average decrease of 27 CD4 cells and mean increase of viral load of 13,00 
viral copies (O’Cleirigh, Ironson, Weiss, & Costa, 2007). Conscientiousness was hypothesized to 
have the strongest association with HIV progression of all the personality types. It was 
hypothesized that as the level of conscientiousness increased slower disease progression would 
be seen as indicated by lower viral loads and higher CD4 counts. 
Five-Factor Model and HIV Progression. In summary, a paucity of studies exist that 
analyze the association of the NEO-PI-R on HIV disease progression. Within the literature 
review of the association of neuroticism on disease progression mixed findings exist. Research 
has pointed to a weak association with more of significance in the negative change on CD4 
counts than viral load measurement (Ironson et al., 2008; Johnson & Neilands, 2007). The direct 
relationship of neuroticism on adverse health outcomes in HIV-seropositive individuals is 
complicated by the finding that individuals who score high in neuroticism are more likely to 
complain about somatic symptoms that do not cause a change in CD4 or viral load (Costa, 1987). 
Thus, a weak association on progression was hypothesized. Mixed findings exist within the 
literature review on the association of extraversion on HIV progression, however a small 
significant result exists. The significance is particularly seen among extraversion’s facets of 
positive affect, gregariousness, and assertiveness (Ironson et al., 2008; Leserman et al., 2002; 
Moskowitz, 2003). Optimism, a component of extraversion, has been shown to have a protective 
effect on progression as measured by CD4 and viral load counts (Milam et al., 2004). Thus, 
extraversion was hypothesized to have one of the strongest associations of the personality 
variables on disease progression. Furthermore, extraversion’s link to social support and coping 
type would play a protective effect within the other aims of this study. Within the literature 
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review of the association of openness on disease progression, studies have shown that openness 
mediates high stress responses in its ability to lower stress and negative self-rated health. Very 
few studies have been conducted looking at the factor of openness on disease progression 
(Penley & Tomaka, 2002; Schneider, Rench, Lyons, & Riffle, 2012; Goodwin & Engstrom, 
2002). However, studies have shown that due to the fact that individuals who score high in 
openness are more affect-sensitive they may also have lower levels of social support and coping 
(McCrae & John, 1992). The association of openness on HIV disease progression was 
hypothesized to be weak. Mixed findings exist within the literature review on the association of 
agreeableness on HIV progression, however a small significant result exists within one study. 
Agreeableness’s facet of altruism is significantly linked to slowed HIV disease progression 
(Millner, 1998). Despite a lack of studies in the area, the connection of agreeableness to the other 
constructs of social support and coping type, agreeableness was hypothesized to be significant 
associated to slower HIV disease progression. Conscientiousness is the most researched trait in 
its association to HIV disease progression. The majority of studies found a large significance in 
its association to slower disease progression, particularly in the facet of achievement striving 
(O’Cleirigh, Ironson, Weiss, & Costa, 2007; Ironson et al., 2008). Thus, conscientiousness was 
hypothesized to be significantly associated with slowed HIV progression in this study. 
Stress & HIV progression  
Stress plays a negative role in HIV/AIDS disease progression and is implicitly connected 
in psychosocial factors such as personality, coping type, and social support. Researchers have 
found similar findings with HIV/AIDS research to that of the association between stress and 
adverse health outcomes in patients with chronic disease. Biologically, during period of high 
stress there is a decrease in killer lymphocytes amongst HIV seropositive individuals (Leserman 
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et al., 1997). In a study of 93 HIV+ men it was found that those who experienced greater life 
stressors, as measured in a semi-structured interview, are more likely to progress to AIDS 
quicker than those who experience less life stressors (Evans et al., 1997). This study also found 
that the risk of early HIV disease progression, as measured by viral load, was doubled with every 
severe life stressor experienced per six-month period (Evans et al., 1997). Conversely, in a study 
of 63 HIV+ individuals those who reported no severe life stressors over the study period 
experienced a smaller decline of CD4 count than those who reported greater life stressors 
(Patterson et al., 1995). Another study measured the stressful life events with a modified 
Psychiatric Epidemiology Research Interview of 82 seropositive gay men and found a correlation 
between higher stressful event scores and faster progression to AIDS, as measured by CD4 
counts (Leserman et al., 2000). 
 Psychological stress is operationalized as the amount that individuals perceive or appraise 
that their demands exceed their ability to cope (Taylor, 1999). The Perceived Stress Scale is a 
measurement of an individual’s perceived stress in their life with higher scores meaning higher 
perceived stress (Cohen & Williamson, 1988). A study of 3,471 individuals analyzed the 
association between the NEO Five-Factor Inventory’s categories of personality and amount of 
stress perceived as measured by Cohen’s Perceived Stress Scale (PSS). Researchers found a 
significant negative association between perceived stress and the traits of extroversion, 
agreeableness, and conscientiousness. A significant positive association was found between 
neuroticism and perceived stress (Ebstrup, Eplov, Pisinger, & Jorgensen, 2011).  
Coping Styles 
Coping is defined as an individual’s cognitive or behavioral responses to a subjectively 
appraised stressful event (Lazarus & Folkman, 1984). In living with a chronic disease such as 
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HIV there are many different stressful aspects such as diagnosis, stigma, side-effects of 
treatment, taking a complex medication, symptoms, finances, progression, and identity 
(Moskowitz & Wrubel, 2005). The challenge with studying coping is the variety of measurement 
and labels for different coping responses. In HIV coping studies COPE and the Ways of Coping 
(WOC) scale are most frequently used. COPE measures 14 different types of coping: active 
coping, planning, suppression of competing activities, restraint, seeking social support for 
instrumental reasons, seeking social support for emotional reasons, positive reinterpretation and 
growth, acceptance, turning to religion, focus on and venting of emotions, denial, behavioral 
disengagement, and mental disengagement (Carver, Scheier, & Weintraub, 1989). The WOC 
measures coping more generally through eight subscales: confrontive, distancing, self-
controlling, seeking social support, self-blame, escape/avoidance, planful problem solving, and 
positive reappraisal (Folkman & Lazarus, 1988).  
As evidenced by the large number of subscales on the WOC and COPE, coping is divided 
into three main types: appraisal-focused, problem-focused, or emotion-focused (Weiten & Lloyd, 
2008).  Appraisal-focused or adaptive cognitive strategies are when an individual changes the 
way they think, their values, or goals in order to lessen the subjective stress (Weiten & Lloyd, 
2008). Problem-focused coping is when the individual deals directly with the cause of their 
problem in order to change or eliminate the source of the stressor. The main strategies of 
problem-focused are taking control, information seeking, and evaluating the situational options 
(Somerfield & McCrae, 2000).  Emotion-focused strategies deal with the management and 
release of the feelings associated with the stressor. The main strategies of emotion-focused 
coping are accepting responsibility or blame, disclaiming, escape-avoidance, exercising self-
control, and positive reappraisal (Brannon & Feist, 2009). Within each of these coping strategies 
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there are positive and negative approaches and thus for the purpose of this meta-analysis coping 
types were grouped into positive, passive, or negative coping type. Coping was analyzed in this 
study due to its potential as mediating factor in slowing HIV disease progression.  
Positive Coping. Positive coping or also known as adaptive or constructive coping 
encompasses a variety of different coping techniques that are all considered to improve 
functioning of the individual. Due to the subjective nature of stressors and thus coping, it is 
difficult to generalize positive coping strategies. However, positive coping is considered to be 
effective coping. Zeidner and Saklofske (1996) found eight criteria that define a coping type as 
effective: resolution of the stressful situation, reduction of physiological reactions, reduction of 
psychological distress, normative social functioning, return to pre-stress activities, well-being of 
self and others affected by the situation, maintaining positive self-esteem, and perceived 
effectiveness. Coping strategies that fit Zeidner and Saklofske’s criteria of effectiveness include 
positive affect, acceptance, positive reappraisal, or cognitive and behavioral engagement.  
Studies have found an association between positive coping strategies and HIV disease 
progression. The largest study analyzed the association of psychosocial factors on immune 
function in their cohort of 773 HIV-seropositive individuals from four U.S. cities. From the 
patient’s interview with a medical professional the researchers were able to measure the positive 
coping strategies of positive affect, finding meaning, and optimism. They found that these 
positive coping strategies were linked to increases in CD4 counts over the five-year study period 
(Ickovics et al., 2006). Another study investigated the role of different coping styles in disease 
progression in a cohort of 65 HIV-positive homosexual men. Researchers found that strongest 
association with the positive strategy of planful problem solving and disease progression with 
increased CD4 counts over an average period of 47 months (Vassend & Esklid, 1998). A small 
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study of 20 HIV-seropositive adults examined the role of positive coping strategies on HIV 
disease progression. Researchers found a significant association with the positive strategies of 
active coping, planning, reinterpretation, growth, and positive thought and higher CD4 counts 
(Biswas, 2011). More recently, a two-year long study with a cohort of 177 HIV+ individuals 
examined the role of positive and proactive coping on disease progression. They found that 
proactive behavior predicted a slower decrease in CD4 counts and lower viral load (Ironson et 
al., 2005). Lastly, some aspects of emotional expression are considered to be positive coping 
strategies although it is important to recognize that this may not be completely generalizable. 
One study facilitated emotional and cognitive processing by having the individual free-write 
about HIV/AIDS. The participants who experienced positive coping through this exercise 
experienced lower viral load and improved CD4 counts over the two-year period (O’Cleirigh et 
al., 2003). In this study positive coping strategies are hypothesized to have one of the most 
significant associations with slowed progression based on the literature review. In studies of 
positive coping there would be an association with lower viral loads and higher CD4 counts. 
 Passive Coping. Passive coping is difficult to operationalize due to the subject nature of 
stress and coping. Some have defined it in terms of the emotional reactions, others with illness 
behaviors, and others the combination (Snow-Turek, Norris, & Tan, 1996). Passive strategies are 
characterized by external reliance and/or helplessness (Nicholas et al., 1992). Type C coping is 
considered passive coping. Type C is characterized in the extreme by non-expression of emotion, 
focus on others’ needs to the exclusion of one’s own (Temoshok, 2004). 
Current studies have not found a conclusive link between passive coping strategies and 
HIV disease progression. Research has shown that the passing coping strategies of denial 
(Goodkin, Fuchs, Feaster, Leeka, & Rishel, 1992), behavioral disengagement, and mental 
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disengagement are more predictive of negative effects on immune functioning in HIV+ 
individuals as opposed to positive coping types (Antoni, Goldstein, Ironson, LaPerriere, Fletcher, 
& Schneiderman, 1995). In a study examining the association of avoidant coping on disease 
progression in 177 HIV-seropositive individuals, researchers found significant correlation. 
Individuals who persistently utilize passive avoidant coping strategies experience a 1.7 times 
greater decline in CD4 and six times greater viral load than individuals in the study who utilize 
positive coping strategies (Ironson et al., 2005). In meta-analysis of type C coping and HIV 
progression, researchers found a significant association with the stage of the disease and disease 
progression. Type C coping type is associated with faster HIV progression only with individuals 
in the mid-stage of HIV progression with CD4 counts of 200-499. However, with HIV+ 
individuals in early stages with CD4 counts 500+ it is not significantly associated with faster 
HIV progression (Vergis & Mellors, 2000). The passive coping strategies’ effects are cumulative 
when a HIV+ individual is also a member of a stigmatized group. For example gay HIV+ 
individuals who conceal their sexual identity, as an ashamed repressive coping technique, have 
an accelerated disease progression in terms of CD4 counts (Wald, Dowling, & Temoshok, 2006). 
In this study passive coping strategies were not hypothesized to have the strongest associations 
with HIV progression due to the subjective nature of passive coping as evidence by the literature 
review. As the number of passive coping strategies increased a non-significant decrease was 
predicted in disease progression as seen with increased viral loads and decreased CD4 counts. 
Negative Coping. Negative coping or also known as maladaptive coping or non-coping 
is considered any strategy that maintains or strengthens the stressor. These techniques may be 
effective in reducing stress in the short-term however not significantly effective in the long-term. 
Some negative coping strategies include disassociation, sensitization, safety behaviors, anxious 
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avoidance, self-medication, and escape. Negative avoidant strategies are associated with 
increased psychological distress (Downe-Wambold & Melansen, 1995) and adverse illness 
outcomes in chronically ill patients (Heim et al., 1997). 
Studies have found an association between negative coping strategies and HIV disease 
progression. Research has shown that negative affect such as pessimism is associated with higher 
viral load over an 18-month period in a cohort of 412 HIV+ individuals (Milam et al., 2004). 
Other components of negative affect include denial and hopelessness. Denial was found to 
predict faster CD4 decline (Ironson et al., 1994), faster overall progression to AIDS (Leserman et 
al., 2000), and mortality (Ironson et al., 1994). A study of 82 HIV+ homosexual men examined 
the impact of hopelessness on disease progression. Researchers found that hopelessness was 
linked to an accelerated rate of increase in viral load counts of HIV+ individuals (Leserman et 
al., 2000). Negative affect is considered emotional-avoidance and is often correlated with 
behavioral escape-avoidance strategies such as drug-use, high-risk sexual behaviors, and alcohol-
use (Lazarus & Folkman, 1984). These emotional and behavioral avoidance strategies can further 
complicated a HIV+ individual’s health with their interference with antiretroviral regimens 
(Ickovics & Chesney, 1997). Studies have found that viral load may be more sensitive to the 
adverse effects of negative coping than CD4 levels (Ironson et al., 2005). In this meta-analysis 
negative coping strategies was hypothesized to have one of the most significant negative 
associations with progression based on the literature review. In studies of negative coping a 
negative relationship was predicted as seen by higher viral loads and lower CD4 counts. 
Coping Type and HIV Progression. In summary, within the literature review of the 
association of positive coping on disease progression a range of findings exist. Studies have 
predominately analyzed the effect of positive coping on progression through the measurement of 
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CD4 count as opposed to viral load. Studies have found that individuals who practice the positive 
coping techniques of positive affect, optimism, finding meaning, planning, problem solving, and 
reinterpretation are likely to experience an increase in CD4 count over time (Ickovics et al., 
2006; Vassend & Esklid, 1998; Biwas, 2011). A strong association between positive coping 
types and slowed HIV progression is hypothesized. Researchers have not found a conclusive link 
between passive coping strategies and HIV disease progression. The passive techniques of 
behavioral disengagement, denial, avoidance, and mental disengagement have been linked to 
faster disease progression as measured by decreases in CD4 and increases in viral load (Antoni et 
al., 1995; Ironson et al., 2005). Due to the subjective nature in operationalizing passive coping, it 
was not hypothesized to have a strong association on disease progression. Within the literature 
review of the association of negative coping on disease progression, mostly negative associations 
exist. The negative coping strategies and affects of pessimism, denial, and hopelessness have 
been linked to faster disease progression and measured by decreases in CD4 counts (Milam et 
al., 2004; Ironson et al., 1994). Thus, it was hypothesized that a strong negative association 
exists between negative coping strategies and disease progression.  
Social Support 
Social support is operationalized as an interaction in which instrumental, recreational, or 
socio-emotional resources are exchanged (Cohen & Syme, 1985) that is considered a positive 
moderator for physical diseases, psychological disorders, and stress (Gottlieb, 1985). There are 
four main functions of social support: companionship, emotional, informational, and tangible 
(Uchino, 2004). Companionship support is the sense of social belonging through the engagement 
of shared social activities (Uhino, 2004). Emotional support makes the individual feel valued 
through affection, acceptance, concern, empathy, and trust (Langford, Bowsher, Maloney, Lillis, 
PSYCHOSOCIAL ASSOCIATIONS ON HIV DISEASE PROGRESSION 27
1997). Information support involves problem-solving assistance through guidance or advice 
(Wills, 1991). Tangible support is concrete assistance through financial assistance or other 
services (Heaney & Israel, 2008). This study divided social support into the broad categories of 
functional and structural support.  
Functional support analyzes the function of people in an individual’s social network 
through the four functions of social support mentioned above (Uchino, 2004).  A study 
conducted with a cohort of 78 seropositive individuals analyzed the relationship between 
functional social support and disease progression as measured by viral load and CD4 
measurements. Researchers found significant correlations between high levels of functional 
social support and high levels of CD4 counts and low viral load levels (Clingerman, 2003). This 
strong correlation between high levels of functional support and slower disease progression is 
seen in the majority of studies analyzing this relationship. A significant relationship between 
functional social support and disease progression was predicted, such that as the level of 
functional social support increases there would be slower disease progression as measured by 
higher CD4 counts and lower viral load measurements. Functional support was predicted to have 
a stronger association with disease progression than structural social support.  
Structural support on the other hand looks at the extent to which an individual is 
integrated in their social network such as through one’s number of social ties (Wills, 1991). A 
study conducted in the United States with a cohort of 414 HIV+ males analyzed the relationship 
between network size, a facet of structural support, on CD4 count as a measure of disease 
progression. Researchers found a strong association between social support network size and 
CD4 count, such that as the size of the network increased CD4 counts increased (Patterson, 
Shaw, Semple, Cherner, McCutchan, Atkinson & Grant, 1996). The researchers attributed this to 
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the fact that a larger network indicates a high degree of sociability, which may be correlated with 
poor health habits.  Other studies have found a positive relationship between network size and 
structural social support and slower disease progression. A longitudinal study of 36 American 
women found a positive association between structural support and HIV progression (Walch, 
1995). Researchers found that as the size of the network increased, there was a positive increase 
in physical health as evidenced by lower viral load measurements. As evidenced by the 
inconsistent findings between structural support and disease progression, it was hypothesized 
that the association between structural social support and disease progression would be weaker 
than the relationship between functional support and progression. Thus, the structural support 
studies were predicted to have a higher average viral load amount and lower CD4 count. 
Social support is linked to positive reductions of psychological distress and has a 
protective effect on physical health. Low social support is associated with an increased risk of 
mortality from physical diseases (Uchino, 2004), while high levels of social support have a 
protective effect on mortality (Holt, Smith, & Layton, 2010). Furthermore, individuals with low 
levels of all types of social support are more likely to have compromised immune functioning 
(Uchino, 2006) and overall health complications (Uchino, 2009). Conversely, high levels of 
social support are associated with greater overall immunity (Cohen, Doyle, Skoner, Rabin, & 
Gwaltney, 1997), age-related decline (Seeman, Lusignolo, Albert, & Berkman, 2001), viral 
susceptibility (VanderPlate, Aral, & Magder, 1988), and faster recovery (Kulik & Mahler, 1993). 
Research has found a positive association between high levels of social support and 
slower HIV progression. A study conducted in Ethiopia with a cohort of 1,815 HIV+ individuals 
analyzed the relationship between social support and CD4 count. Researchers found a positive 
association between social support and CD4 gain over the study period (Alemu, Mariam, Tsui, 
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Ahmed & Shewamare, 2012). Leserman examined the role social support plays on multiple 
measures of HIV progression in 96 HIV+ homosexual men over a nine-year period. Lower 
cumulative average social support predicted faster negative disease progression (Leserman et al., 
2002). This is complicated by the fact that diagnosis with AIDS is associated with lower levels 
of practical and emotional support from family members (Kelly, Raphael, & Statham, 1996). The 
overall inadequate social support causes adverse physiological and psychological consequences 
(Leserman et al., 1996). The purpose of this meta-analysis was to examine the less researched 
question of what type of social support (functional or structural) is linked to slower HIV disease 
progression. It was hypothesized that a significant relationship between both types of social 
support and the outcome variables would be seen. Higher levels of both types of social support 
would be associated with slower disease progression as evidenced by lower viral loads and 
higher CD4 counts. Furthermore, a significant difference between the two types of social support 
was predicted in terms of their strength of association with disease progression. Higher levels of 
functional social support are predicted to have a stronger association with disease progression 
than high levels of structural support. 
Current Study 
The current study explored the association between the psychosocial factors of 
personality, coping type, and social support and HIV/AIDS disease progression. A meta-analytic 
methodology was employed in this study due to a wide range of conflicting views in the research 
in the last twenty years investigating associations between psychosocial factors and HIV disease 
progression (Chida & Vedhara, 2009). Conflicting results may be due to differences in 
operationalizing concepts of social support and coping styles. Through the meta-analysis method 
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employed in this study it would conclusively answer the nature of the psychosocial associations 
on HIV disease progression.  
 It was hypothesized that a significant association would be found between the five 
personality variables and HIV disease progression as measured by viral load and CD4 count. A 
significant association would indicate that very high or very low levels of the trait had a 
significant effect on the outcome variables and thus disease progression. It was hypothesized that 
the association would be the strongest with the personality variables of conscientiousness, 
agreeableness, and extraversion in order of strength of hypothesized significance. For the 
variables of conscientiousness, agreeableness, and extraversion a negative relationship was 
hypothesize, such that as the trait increases, disease progression would decrease (lower viral load 
and higher CD4 count). 
 It was hypothesized that a significant relationship would be found within the variable of 
coping and each coping type (negative, passive, and positive) and the outcome variables. In 
addition, it was hypothesized that the association would be the strongest with positive and 
negative coping. For positive coping, a negative relationship was hypothesized such that as 
positive coping increased there would be less disease progression as operationalized by higher 
CD4 counts and lower viral load. For negative coping, a positive relationship was hypothesized 
such that as negative coping increased there would be greater disease progression as 
operationalized by lower CD4 counts and higher viral load.  
Lastly, it was hypothesized that a significant relationship would exist between the 
variable of social support as well as between each type of social support (structural support and 
functional support) and outcome variables. For higher levels of both functional and structural 
support, a negative relationship was hypothesized such that there would be less disease 
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progression as operationalized by lower viral loads and higher CD4 counts. There would be a 
significant difference between structural and functional support in terms of disease progression, 
as measured by the outcome variables. High levels of functional support would be more strongly 
negatively related to slower disease progression than high levels of structural support.  
Method 
Study selection 
Studies were found through a systematic search of general psychology and medical 
computerized databases: PsycINFO and PubMed. The main search keyword strategy was (AIDS 
or HIV) AND (psych* or personality or coping or social support or anxiety or social support). In 
addition, the reference lists of found publications were reviewed. 
Inclusion and exclusion criteria  
The criteria for inclusion were: (1) an English language full-length publication in a peer-
reviewed journal; (2) studies conducted in 1996 to 2013; (3) adult study participants (18 years or 
older); (4) outcome variables measured as CD4 count or viral load; (5) if more than one 
psychosocial factor or outcome variable were studied then the samples are included separately.  
Figure 1 summarizes the results of the systematic search. 
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Quality assessment 
  The quality of each study that met all the selection criteria was assessed. The quality 
assessment was based on an existing checklist used in similar health psychology meta-analyses 
(Laupacis et al., 1994; von Elm et al., 2007). Articles were assessed on a four-point scale (4 = the 
highest quality and 0 = lowest quality). The four criteria were: 1) representative sampling or 
random recruitment of participants; 2) outcome variables measured by validated clinical 
examinations or instruments; 3) independent variables measured by validated clinical 
examinations or instruments; 4) control for possible covariate such as sex, socio-economic status 
(SES), race, age, and adherence and use of antiretroviral (ARV).  A study was considered high 
quality if it met three or more of the quality assessment criteria. The quality scores for each 
individual study are displayed in Appendix A. In the entire meta-analysis, 32.51% were 
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considered excellent (quality score of four), 54.91% were considered good (quality score of 
three), 11.66% were considered fair (quality score of two), and 0.92% were considered poor 
(quality score of one).  
Data coding 
  A coding guide was developed for the meta-analysis of the studies to identify information 
possible moderating effects and potential directions for future study. Of the 4,632 amount of 
articles found in the literature search 110 articles met all the inclusion and exclusion 
characteristics and were included in this study. A standardized coding form was used for each 
study coding for study information (cohort size, year, location), study methodology (e.g., 
longitudinal) covariates (age, sex, SES, race, ARV usage, sexual orientation, disease status), 
outcome measurement (CD4+ lymphocyte count or viral load), psychosocial factor (e.g., coping 
type, personality, or social support) and measurement scale, quality assessment score, and effect 
size. The complete list of variable is displayed in Appendix C.  
Data analyses 
All analyses were conducted using the software program Statistical Package for the 
Social Sciences (SPSS). For each study the correlation coefficient (r) was calculated as the effect 
size. Meta-analytic R was chosen as measure of effect size due to its widespread applicability to 
different data types and ease of conversion and computation. In the case where a study did not 
include an r effect size one was calculated through a study’s descriptive statistics, t statistics, 
tables of counts, and F ratios (Rosenthal, 1991). The meta-analytic procedures were conducted as 
recommended by Lipsey (Lipsey & Wilson, 2001). Weighted average effect sizes were 
calculated through weighting studies’ effect sizes proportionally with their degrees of freedom 
(Rosenthal & DiMatteo, 2001). In this study, each psychosocial category measure (e.g. coping, 
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personality) was viewed as a separate construct and thus multiple effect sizes may have been 
necessary within one study.  
A random-effects model was used in this study’s analysis due to the variability of 
distribution of effect sizes within study populations. Heterogeneity was measured in order to 
determine the degree of variation within the study outcome variables between studies to see the 
inconsistency of studies’ results. It was measured through the calculation of the statistic Q. If the 
Q tests had a significant results then the moderating factors were the cause of the variability of 
the study. 
Due to the nature of the methodology of meta-analysis publication bias was a concern. 
Publication bias is the greater likelihood for studies with significant results to be published thus 
causing a positive bias within the literature. In order to see the degree to which publication bias 
exists within the selected studies the fail-safe N, sensitivity analysis, and the degree of 
asymmetry were calculated. The fail-safe N calculates the number of unpublished studies with 
non-significant findings necessary to reduce the overall significant effect in the meta-analysis to 
be non-significant. A large fail-safe N indicates that is unlikely that publication bias is occurring 
and that the effect is represented by a Type I error. A sensitivity analysis is a model used to 
measure the likelihood of a study being published according to the characteristics of each study’s 
cohort populations (Vevea and Woods, 2005). Lastly, the degree of asymmetry was calculated 
with Egger’s unweighted regression asymmetry test (Egger et al., 1997).  This test detected 
whether the data had an asymmetric funnel shape or not. Asymmetry would mean a positive 
result bias due to the relationship of study size and effect size. A positive result bias occurs when 
studies are more likely to be published when a significant result is found, thus the selected 
studies would have an overall bias towards significant data. An unbiased symmetric funnel plot 
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would be funnel shaped due to the data point cloud symmetrically organized around the effect 
size of the study population. 
Results 
Meta-Analytic Procedures 
  
 Effect Size. All effect sizes were calculated to compare with Pearson r correlation 
coefficient (r) in order to have a common effect size across the studies. Most studies analyzed 
provided the value of Pearson’s r. In the case that a study did not provide Pearson’s r it was 
calculated using Lipsey and Wilson (2000) equation 
ESr = (N Σxi yi – Σ xi Σ yi )/( √( N Σx12 – (N Σxi )2(N Σyi 2 – (N Σyi )2)     (1) 
where N is the total sample size for the study and the individual level data for the study are the 
variables x and y.  
 Transformations. Effect sizes were calculated for each individual study for comparison 
between the independent variables. Appendix A displays the unweighted effect size for each 
study. Each effect size was transformed with the Fisher’s Zr transformation of the Pearson’s r 
correlation. This transformation was performed to convert Pearson’s r to the normally distributed 
variable Z, which was used for computing confidence intervals. 
ESzr = .5 [ln (1+r) – ln (1-r)]                (2) 
After Fisher’s transformation the mean unweighted effect sizes were calculated for each 
domain analyzed (personality, coping type, and social support) by dividing total effect size by 
the n, the number of effect sizes in the domain. The mean unweighted effect size was calculated 
for the entire domain and each of the different groups based on the domain’s independent 
variable. The mean unweighted effect size were not used in further analysis due to the large 
amount of bias seen in these studies as well as low power (Lipsey & Wilson, 2001). Weighted 
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mean effect sizes were used instead as they inherently have less bias than unweighted estimates 
(Lipsey & Wilson, 2001).   
 The calculation of mean weighted effect sizes involved many different steps. The first 
step was calculating the error for each individual study.  
Standard Error = 1/(√N-3)         (3) 
Hedge’s states the best method of weighing is through calculating inverse variance weights 
(Lipsey & Wilson, 2001). The inverse variance weight (wi) is the inverse of the standard error 
for each individual effect size. As advised in Lipsey and Wilson, the following calculations were 
made for each domain using SPSS command language. 
1. wi  x ES = wes            (4) 
2. wi x ES2 = wessq                       (5) 
3. wi2= wsqi                                         (6) 
From these SPSS calculations the mean weighted effect size and standard error of the mean 
effect size, were calculated:  
ES = (Σ (w x ES) / Σ w)                      (7) 
 SE = √ (1/ Σ w)               (8) 
The mean effect size, standard error of the mean effect size, Z-test for the mean effect 
size (9), and 95% confidence intervals (10) were calculated for each group in each domain. For 
example in the coping domain, the mean effect size was calculated for: CD4 positive, CD4 
passive, CD4 negative, VL positive, VL passive, VL negative, total VL, total CD4, total positive, 
total passive, and total negative. 
Z = ES / SE                (9) 
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Lower CI = ES – 1.96 (SE)          (10) 
Upper CI = ES +1.96 (SE) 
 
 Homogeneity Analysis. Homogeneity analyses were conducted in order to determine 
whether the assumption that all the effect sizes were estimating the same population mean was 
valid. If homogeneity (Q) were statistically significant then it is rejected, the distribution of 
effect sizes in the domain was considered heterogeneous. This means that there was greater 
variation between effect sizes than one would predict purely from sampling error (Lipsey & 
Wilson, 2001).  The formula for Q is: 
Q  = Σ (wxES2) – [(Σ (wxES)2/( Σw)]   df = k -1       (11) 
Q was evaluated using the Chi-Square critical values. A calculated Q that was less than the 
critical value for Chi-Square fails to reject the null hypothesis of homogeneity. Heterogeneous 
distributions were then used to analyze the excess study variability assuming that the variability 
was random and fit the random effects model (Lipsey & Wilson, 2001). For each domain with a 
significant Q value, heterogeneous distributions were analyzed in order to examine the difference 
between the levels of the independent variables.  The variables were considered significant if Qb, 
the amount of difference between levels of the variable, was significant at the alpha level (α = 
.05). The sum of the individual group Q’s within the domain were used to compute the Qb,  
Qwithin = Qgroup1 + Qgroup 2  df = k – j         (12) 
Qbetween = Qtotal – Qwithin  df = j – 1         (13) 
where k is the number of effect sizes in the domain and j is the number of groups. The mean 
effect size, standard error, and confidence intervals were calculated for each group (equation 7, 
8, and 10).  
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 Random Effects Model. A random effects model was used in this meta-analysis due to 
the significant total Q measurements, which indicated excess variability across the effect sizes in 
the domain due to random differences. The random effects variance component (Vθ) was 
calculated from the Q statistic: 
Vθ = [Qt  - (k – 1)] /[ Σw – (Σw2/ Σw)]          (14) 
The random effects variance component (Vθ) was used to calculate the random effects model 
weight of each study. 
W = 1/ (sei2 + Vθ )             (15) 
The sei
2 
was the standard error calculated including the random variance. Using the random 
effects variance component the mean effect size, standard error, confidence intervals, and Q 
statistics (Equations 7,8, 10, 11, 12, and 13).  
Description of Studies and Effect Sizes Included in the Meta-Analysis 
One hundred and eleven studies were included in the three meta-analysis domains 
(Appendix A). In the social support domain there were forty-two studies, fourteen in the 
personality domain, and fifty-five in the coping type domain.  Some studies included multiple 
correlations between outcome measurement and the other independent variables and they were 
reported independently as a separate case. The 111 studies led to 326 measures of effect size 
comparisons (111 in social support, 46 in personality, and 169 in coping). Across the studies and 
domains, the total sample size was 50,514 with 4,889 in personality, 22,203 in social support, 
and 23,422 in the domain of coping. The range of sample sizes for CD4 counts in the personality 
domain was from 24 to 258 participants (M = 107.54, SD = 53.37). The range of sample sizes for 
viral load measurements in the personality domain was from 56 to 119 participants (M = 99.29, 
SD = 19.89). The range of sample sizes for CD4 counts in the coping domain was from 18 to 871 
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participants (M = 129.51, SD = 112.13). The range of sample sizes for viral load measurements 
in the coping domain was from 41 to 412 participants (M = 172.14, SD = 123.68). The range of 
sample sizes for CD4 counts in the social support domain was from 12 to 3,736 participants (M = 
180.73, SD = 394.09). The range of sample sizes for viral load measurements in the social 
support domain was from 54 to 3,736 participants (M = 314.63, SD = 912.88). Table 1 displays 
the descriptive information for each data set such as the mean unweighted effect sizes and range 
of effect size scores. 
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Table 1 
Descriptive Statistics for Effect Sizes Prior to Meta-Analyses 
 
Group               # of Effect Sizes        N             Range          Mean Unweighted ES 
Social Support     
CD4 Structural 32 7,799 -.320 to .681 0.042 
CD4 Functional 63 9,370 -.610 to .575 0.020 
VL Structural 6 4,102 -.247 to .750 0.321 
VL Functional 10 932 -.300 to .326 0.052 
 
Personality 
    
CD4 Neuroticism 11 1,363 -.131 to .234 0.051 
CD4 Extraversion 5 571 -.306 to .138 -0.056 
CD4 Openness 4 467 .031 to .260 0.133 
CD4 Agreeableness 9 847 -.070 to .328 0.147 
CD4 Conscientiousness 10 946 -.157 to .333 0.123 
VL Neuroticism 1 104 - 0.001 
VL Extraversion 1 104 - -0.030 
VL Openness 1 104 - -0.025 
VL Agreeableness 1 104 - 0.009 
VL Conscientiousness 3 279 -.284 to .015 -0.161 
 
Coping 
    
CD4 Positive 81 10,644 -.341 to .913 0.114 
CD4 Passive 25 2,672 -.340 to .520 0.059 
CD4 Negative 27 3,909 -.443 to .439 -0.006 
VL Positive 22 3,875 -.209 to .469 0.097 
VL Passive 5 721 .167 to .243 0.217 
VL Negative 9 1,601 -.180 to .750 0.179 
 
 Due to the bias inherent in mean unweighted effect sizes, all the effect sizes were 
weighted by sample size (Lipsey & Wilson, 2001). Further analyses on the data sets involved 
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only the mean weighted effect sizes in order to increase the reliability of the findings. Table 2 
lists the mean unweighted and weighted effect sizes for each group.  
Table 2 
Mean Effect Sizes 
Group                        Mean Weighted ES                     Mean Unweighted ES           
Social Support   
CD4 Structural 0.011 0.042 
CD4 Functional 0.028 0.020 
VL Structural 0.037 0.321 
VL Functional 0.060 0.052 
Personality   
CD4 Neuroticism 0.081 0.051 
CD4 Extraversion -0.122 -0.056 
CD4 Openness 0.166 0.133 
CD4 Agreeableness 0.106 0.147 
CD4 Conscientiousness 0.079 0.123 
VL Neuroticism 0.001 0.001 
VL Extraversion -0.030 -0.030 
VL Openness -0.025 -0.025 
VL Agreeableness -0.009 0.009 
VL Conscientiousness -0.141 -0.161 
Coping   
CD4 Positive 0.083 0.114 
CD4 Passive 0.044 0.059 
CD4 Negative -0.011 -0.006 
VL Positive 0.063 0.097 
VL Passive 0.212 0.217 
VL Negative 0.173 0.179 
 
Analyses of mean weighted effect sizes show that in all the data sets, the viral load 
measurements had significantly higher effect sizes than the CD4 effect sizes. In the social 
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support data set the functional support type was significantly higher than structural social 
support. In the coping data set, the negative coping type had the highest average effect size 
followed by passive coping and lastly positive coping. In the personality data set, openness was 
significantly higher than the other traits followed by extraversion, agreeableness, neuroticism, 
and conscientiousness. In Table 3, the weighted mean effect sizes are displayed as well as 
confidence intervals, standard error, and tests of homogeneity. The variable Q analyzed how 
heterogeneous the data set was, meaning greater variation between the different effect sizes than 
normally predicted from sampling error. A Q score larger than the calculated critical Chi-Square 
value indicated that the data was more heterogeneous than one would normally expect and the 
hypothesis of homogeneity was rejected. It is also important to note that for a few variables such 
as CD4 negative coping and VL conscientiousness the confidence interval (CI) ranged from a 
negative to positive integer. This may cause a potential inconsistency in the data set (Lipsey & 
Wilson, 2001).  
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Table 3 
Mean Effect Sizes 
Group               Mean Weighted ES           SE            95% CI                     Q      
Social Support     
CD4 Structural 0.011 0.011 0.02 to 0.06 81.88 a 
CD4 Functional 0.028 0.010 0.01 to 0.05 209.9 a 
VL Structural 0.037 0.016 0.01 to 0.06 72.83 a 
VL Functional 0.060 0.033 0.01 to 0.07 17.75 a 
Personality     
CD4 Neuroticism 0.081 0.027 0.03 to 0.13 12.78 a 
CD4 Extraversion -0.122 0.042 -0.21 to -0.04 21.07 a 
CD4 Openness 0.166 0.047 0.07 to 0.26 4.48 a 
CD4 Agreeableness 0.106 0.03 0.04 to 0.17 15.13 a 
CD4 Conscientiousness 0.079 0.03 0.01 to 0.14 23.84 a 
VL Neuroticism 0.001 0.10 -0.19 to 0.20 0.001  
VL Extraversion -0.030 0.10 -0.23 to 0.17 0.001 
VL Openness -0.025 0.10 -0.23 to 0.17 -0.003 
VL Agreeableness -0.009 0.10 -0.19 to 0.20 4.138 
VL Conscientiousness -0.141 0.10 -0.34 to 0.05 2.853 
Coping     
CD4 Positive 0.083 0.010 0.06 to 0.10 394.1 a 
CD4 Passive 0.044 0.020 0.01 to 0.09 108.0 a 
CD4 Negative -0.011 0.016 -0.04 to 0.02 72.25 a 
VL Positive 0.063 0.016 0.03 to 0.09 101.8 a 
VL Passive 0.212 0.038 0.14 to 0.29 -0.054 
VL Negative 0.173 0.025 0.12 to 0.22 23.38 a 
a Hypothesis of homogeneity is rejected at p = 0.05  
 Random Effects Model. A random effects model analysis was performed on each of the 
three domains in order to adjust the sample statistics to include excess variability across the 
effect sizes in the domain. By including the excess variability the size of the effect sizes 
increased, making it more likely for significant interactions to occur between the independent 
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variables. The random effects variance (Vθ) was calculated from the Q statistics for each domain 
or the degree to which the domain is heterogeneous. The variables that were considered 
significantly heterogeneous were marked in Table 3. In Table 4, the new values for each of the 
levels of the independent variable after the analysis was rerun with the random effects variance 
component included in the appropriate calculations. 
Table 4 
Random Variance Component Mean Effect Sizes 
Group               Mean Weighted ES           SE            95% CI                     Q      
Social Support     
CD4 Structural 0.044 0.024 -0.01 to 0.09 45.97a 
CD4 Functional 0.017 0.021 -0.02 to 0.06 88.25 a 
VL Structural 0.302 0.252 -0.19 to 0.80 2.794 
VL Functional 0.057 0.252 -0.44 to 0.55 -0.299 
Personality     
CD4  0.083 0.027 0.03 to 0.14 -3.748  
VL  -0.066 0.045 -0.15 to 0.02 -4.143 
Coping     
CD4 Positive 0.064 0.023 0.02 to 0.11 98.68 
CD4 Passive 0.050 0.043 -0.03 to 0.13 23.70  
CD4 Negative -0.006 0.029 -0.06 to 0.05 30.70  
VL Positive 0.072 0.020 0.03 to 0.11 80.39a 
VL Passive 0.179 - - -119.5 
VL Negative 0.122 - - 35.64a 
a Hypothesis of homogeneity is rejected at p = 0.05  
Social Support 
 Interaction of social support and HIV progression. A significant relationship between 
social support types and the outcome variables was hypothesized. For higher levels of both 
functional support and structural support, a negative relationship was hypothesized such that 
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there would be slowed disease progression as operationalized by lower viral loads and higher 
CD4 counts. There would also be a significant difference between mean effect sizes of structural 
and functional support in terms of disease progression, as measured by the outcome variables. 
High levels of functional support would be more strongly negatively related to slower disease 
progression than high levels of structural support. 
A 2 x 2 ANOVA was performed on this data set in order to test the nature of the 
interaction between outcome measurement (CD4 versus viral load) and type of social support 
(functional support vs. structural support). The transformed variable (ESzr) was used as the 
measure of effect size. Consistent with the hypotheses, there was a significant interaction 
between outcome measurement and type of social support seen in the effect sizes, F 
(1,107)=5.731, MSe = .056, η2 = .051, p = .018.  Effect sizes for studies that utilized CD4 count 
as the outcome measurement had significantly higher mean effect sizes measuring functional 
support (M = 0.214, SD = 0.227) than structural social support (M = 0.047, SD = 0.204). This 
means that with disease progression measured by CD4 cell counts, high levels of functional 
support were more important than high levels of structural social support in increasing CD4 
counts and thus slower progression. Effect sizes for studies that utilized viral load had 
significantly higher mean effect sizes for structural support (M = 0.396, SD = 0.494) than 
functional support (M = 0.053, SD = 0.178). This indicated that functional support had a greater 
protective effect on disease progression, as there were smaller increases in viral load with 
functional support than structural support. These results relate to the hypothesis of which type of 
social support had the strongest effect on HIV disease progression. 
Effect of outcome measurements. Consistent with the hypothesis, there was a 
significant main effect for outcome measurement, F (1,107) = 8.209, MSe = .056, η2 = .071, p = 
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.005, such that the outcome measurement, CD4 count (M = 0.301, SD = 0.219) had significantly 
higher mean effect sizes than viral load (M = 0.1813, SD = 0.36). This indicated that 
measurements of CD4 count had a stronger association between the social support variables and 
disease progression than studies that utilized viral load count. 
Effect of social support type. Consistent with the hypothesis, there was also a 
significant main effect for social support type, F (1, 107) = 7.745, MSe = .056, η2 = .067, p = 
.006, such that the effect sizes for structural support (M = 0.1022, SD = 0.2202) were rated 
significantly higher than for functional support (M = 0.0257, SD = 0.248). This suggests that the 
studies analyzing structural support had a stronger association with the outcome variables than 
functional support. These results further answer the hypothesis of which type of social support 
had the strongest protective effect on HIV progression. 
 Potential moderating variables. A correlation matrix was created in order to see if there 
were any covariates that may be suppressing the significance of the effect size. The only 
significant Pearson correlation with the transformed variable ESzr is age (r(111) = 0.221, p = 
0.20).  
Sensitivity analyses. Tests of homogeneity were performed on the social support data 
set. The calculate Q from both the CD4 and viral load effect size groups was larger than critical 
value for Chi-Square (Table 4). Thus, the null hypothesis of homogeneity was retained. This 
means that variability across effect sizes exceeded what would be expected based on sampling 
error. Heterogeneous distribution analysis was used as a follow up test in order to analyze the 
excess between study effect size variability. It assumes that the variability in this data set was 
random and fit a random effects model.  Among the CD4 set of effect sizes in the personality 
data set, the Qw (291.77) was greater than critical Chi-square values, thus a random effects 
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model was used. The random effects model assumes that the variability between effect sizes was 
due to sampling error in the individual studies and variability in a true population’s effects.  The 
Qb (0.907) was less than the critical Chi-square value. This means that the variability between 
the studies was homogenous and thus excess variation or heterogeneity was not seen among this 
group. Among the viral load set of effects the Qw (90.58) was larger than the critical Chi-square 
value but the Qb (0.39) was smaller than the critical Chi-square value. Thus, a random effects 
model was performed on both groups of data. 
Lastly, sensitivity analyses were performed on the data set to analyze the publication 
biases inherent in meta-analyses. The fail-safe N for the social support was calculated to be 1,720 
additional studies must be found in order to increase the p value for this data set above 0.05. The 
Egger’s funnel plot is as a visual plot of publication bias for the data set. The funnel plot for the 
social support data set can be seen in Appendix B. The funnel plot can be interpreted as a well 
behaved data set. The bottom of the plot is made up of the studies with smaller sample sizes and 
spread evenly on both sides of the average effect size. The larger N studies tend towards the 
average. This symmetrical funnel does not indicate that publication bias nor small study effects 
were seen in this data set. 
Personality 
Interaction of personality and HIV progression. A significant relationship was 
hypothesized between the five personality types and HIV disease progression as measured by 
viral load and CD4 count. A significant relationship would indicate that very high or very low 
levels of the trait had a significant effect on the outcome variables and thus HIV disease 
progression. It was hypothesized that the association would be the strongest with the personality 
variables of conscientiousness, agreeableness, and extraversion in order of strength of 
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hypothesized significance. For the variables of conscientiousness, agreeableness, and 
extraversion a negative relationship was hypothesize, such that as the trait increases, disease 
progression would decrease as seen by lower viral load and higher CD4 counts. 
A 2 x 5 ANOVA was performed on this data set in order to test the nature of the 
interaction between outcome measurement (CD4 vs. viral load) and personality type 
(neuroticism, extraversion, openness, agreeableness, and conscientiousness). The weighted 
average mean effect size including random variance component was used as the measure of 
effect size. Contrary to the hypotheses, mean effect sizes for studies that utilized viral load, there 
was a non-significant relationship between outcome measurement and personality type, F (4,6) = 
.376, MSe = 35.354, p = .816. Contrary to the hypotheses, mean effect sizes for studies that 
utilized CD4 count as their outcome measurement, there was a non-significant relationship 
between outcome measurement and personality type, F (4, 34) = 2.006, MSe = 28.523, p =  .116. 
These non-significant relationships between outcome measurements and personality types 
indicate that personality type has a weak effect on disease progression. These results answer the 
hypothesis of whether personality had a significant effect on HIV disease progression as 
measured by viral load and CD4 counts. 
 Differences between personality types. LSD and Bonferroni were used as follow up 
tests. Contrary to the hypothesis in analyzing the CD4 count studies with LSD, there was a 
significant difference between CD4 extraversion (M = -2.87, SD = 8.65) and three of the 
personality types: CD4 openness (M = 5.30, SD = 5.01), CD4 Agreeableness (M = 4.70, SD = 
4.40), and CD4 conscientiousness (M = 3.82, SD = 5.37). It was hypothesized that extraversion 
would be the third strongest personality trait and have a beneficial relationship with HIV 
progression. However, based on the follow-up findings extraversion as measured by CD4 counts 
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had a detrimental effect on progression. However, after utilizing Bonferroni’s there were not any 
significant findings for the CD4 outcome measurements and personality. This suggests a weak 
relationship between each of the different personality types and disease progression. These 
results answer the hypotheses of which personality type had the strongest beneficial relationship 
on disease progression. 
In analyzing the mean effect size of the viral load studies with LSD, a few significant 
differences between personality types were found. Consistent with the hypotheses, the trait with 
the largest beneficial effect on HIV progression was viral load conscientiousness (M = -9.72, SD 
= 9.70) followed by viral load extraversion (M = -2.24, SD = 7.41), and viral load openness (M = 
-1.87, SD = 7.41) in terms of the size of the decrease of viral load. Consistent with the 
hypotheses, conscientiousness and extraversion were predicted to be beneficial on HIV 
progression however; openness was not predicted to be beneficial in terms of decrease in viral 
load amounts.  Both neuroticism (M = 0.075, SD = 7.41) and agreeableness (M = 0.67, SD = 
7.41) had a negative effect on HIV progression causing an increase in viral load amounts. This 
was partially consistent with the hypotheses, as it was predicted that neuroticism would have a 
negative effect on HIV progression however agreeableness was predicted to have a beneficial 
effect on viral load amounts. Agreeableness had a larger negative effect on viral load amounts 
than neuroticism. The effect conscientiousness had on disease progression was significantly 
different than the four other personality traits. In comparing conscientiousness to neuroticism 
and agreeableness, one can see that conscientiousness has a stronger beneficial relationship with 
disease progression while neuroticism and agreeableness have an adverse relationship with 
progression. Conscientiousness has a negative relationship with disease progression as measured 
by viral load such that as conscientiousness increases, viral load decreases. However, for 
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neuroticism and agreeableness there is a small positive relationship causing a detrimental 
relationship with progression such that as the two traits increase, viral load does as well. In 
comparing conscientiousness to extraversion and openness, one can see that conscientiousness 
has a stronger beneficial effect on HIV progression than the two other variables (extraversion 
and openness) as evidenced by lower viral load amounts. As the personality trait with the second 
strongest positive effect on HIV progression, viral load extraversion is also significantly different 
than viral load agreeableness. This indicates that extraversion has a stronger beneficial 
relationship with progression than the adverse relationship of agreeableness on progression as 
measured by viral load. Furthermore, this significant difference indicates that conscientiousness 
has a stronger negative relationship on progression than extraversion such that an increase in 
conscientiousness decreases viral load more so than an increase in extraversion. As the 
personality trait with the third strongest positive effect on HIV progression, viral load openness 
is also significantly different than viral load agreeableness and conscientiousness. This suggests 
that openness has a strong beneficial relationship on disease progression, as openness increases 
viral load decreases. However, openness does not have as strong of protective relationship on 
progression as conscientiousness, as seen by greater decrease in viral load amounts.  
Potential moderating variables. A 2 x 5 ANCOVA was performed on this data set to 
test the nature of the interaction between outcome measurements (CD4 versus viral load) and 
personality types (neuroticism, extraversion, openness, agreeableness, and conscientiousness) 
while controlling for the covariate sexual orientation. No significant covariates existed for CD4 
effect sizes that include random variance, however sexual orientation was a significant covariate 
for viral load effect sizes including random variance (r = .769, p = 0.043). Thus an ANCOVA 
was performed on the weighted mean viral load effect size including random variance. Using 
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ANOVA, there was no significant interaction between outcome measurement and personality 
type in the random variance weighted mean effect sizes, F (4,6) = .376, MSe = 35.354, p = .816. 
Even after controlling for the significant covariant, sexual orientation, there still was a non-
significant relationship between viral load outcome and personality type F (4,7) = .102, MSe = 
95.735, p = .965.  
Sensitivity analyses. Tests of homogeneity were performed on the personality data set. 
The calculated Q from both the CD4 and viral load effect size groups were larger than the critical 
value for Chi-Square (Table 4). Thus, the null hypothesis of homogeneity was retained. This 
means that variability across effect sizes exceeded what would be expected based on sampling 
error. Heterogeneous distribution analysis was used as a follow up test in order to analyze the 
excess between study effect size variability. It assumed that the variability in this data set was 
random and fit a random effects model.  Among the CD4 set of effect sizes in the personality 
data set, the Qb (26.25) and Qw (77.03) were both greater than critical Chi-square values, thus a 
random effects model was used. The random effects model assumes that the variability between 
effect sizes was due to sampling error in the individual studies and variability in a true 
population’s effects.  Among the viral load set of effects, the Qb (2.85) and Qw (4.14) were both 
less than the critical Chi-square values. This means that the variability between the studies was 
homogenous and thus excess variation or heterogeneity was not seen among this group. 
Therefore, one can be confident that in studies that utilized viral load as their outcome 
measurement that all the effect sizes were similar enough to each other in order to make a 
meaningful data set. A meaningful data set is one that varies between studies less than due to 
random chance thus the results can be explained.    
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Lastly, sensitivity analyses were performed on the data set to analyze the publication 
biases inherent in meta-analyses. The fail-safe N for the personality data set was calculated to be 
182 additional studies, which must be found in order to increase the p value for this data set 
above 0.05. The Egger’s funnel plot is as a visual plot of publication bias for the data set. The 
funnel plot for the personality data set can be seen in Appendix B. The funnel plot was 
interpreted as an asymmetrical data set. This means that a relationship between treatment effect 
and study size may be occurring. It could also signify that there are some instances of publication 
bias, which were further reinforced by the low fail-safe N number. The fact that the majority of 
the data points exist outside of the positive and negative 3 SD confidence interval lines, can be 
potentially interpreted as a heterogeneous data set that may have high instances of publication 
bias. It is also important to note the criticism of funnel plots, in that they were able to change 
quite dramatically in appearance and interpretation based on the scale of y-axis. Potentially, if 
the y-axis variable changes from ES to the weighted mean random variance component effect 
size the plot would be interpreted differently. Therefore, due to the large amount of ways in 
which one can potentially manipulate the data in an Egger’s plot, the interpretation of the graph 
should not be solely analyzed as a predictor of publication bias.  
Coping  
Interaction of coping and HIV progression. It was hypothesized that a significant 
relationship would be found with the overall variable of coping and each coping type (negative, 
passive, and positive) and the outcome variables (viral load and CD4). In addition, it was 
hypothesized that the association would be the strongest with positive and negative coping. For 
positive coping, a negative relationship was hypothesized such that as positive coping increased 
there would be less disease progression as operationalized by higher CD4 counts and lower viral 
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load. For negative coping, a positive relationship was hypothesized such that as negative coping 
increased there would be greater disease progression as operationalized by lower CD4 counts 
and higher viral load.  
A 2 x 3 ANOVA was performed on this data set in order to test the nature of the 
interaction between outcome measurement (CD4 vs. viral load) and coping type (positive coping, 
passive coping, and negative coping). The weighted average mean effect size was used as the 
measure of effect size. Consistent with the hypothesis, there was a significant interaction 
between outcome measurement and coping type, F (2,163) = 3.776, MSe =781.795, η2 = .044, p 
= .025. This means that regardless of the coping type, coping has a significant effect on HIV 
progression. 
Consistent with the hypothesis, in the mean effect sizes for studies that utilized CD4 
counts a significant effect was seen on HIV progression among the different coping types, F (2, 
130) = 3.449, MSe = 28.156, p = .035. This means that each type of coping was significantly 
different to each other in terms of mean effect sizes. Consistent with the hypotheses among the 
CD4 count studies, positive coping (M = 10.675, SD = 30.46) had the greatest mean followed by 
passive coping (M = 4.58, SD = 24.29) and negative coping (M = -1.5978, SD = 19.20). The 
greatest mean effect size means that positive coping had the greatest beneficial effect on HIV 
progression through an increase in CD4 counts. With positive coping strategies the rate of CD4 
increase is more than twice as large as the rate of increase for passive coping. Negative coping’s 
mean effect size is negative thus there it has a detrimental effect on progression, as seen by the 
decrease in CD4 count. 
However, in the effect sizes for studies that utilized viral load as the outcome 
measurement, a non-significant effect was seen on HIV progression among the different coping 
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types contrary to the hypothesis F (2, 33) = 1.769, MSe = 35.434, p = .186. Among the viral load 
studies, positive coping (M = 10.85, SD = 33.48) was significantly different than passive (M = 
30.51, SD = 8.60) and negative coping (M = 30.33, SD = 26.53) in terms of mean effect sizes. 
This smaller significant mean effect size means that positive coping has a beneficial effect on 
progression through smaller increase in viral load than the two other coping types. Passive and 
negative coping do not differ significantly from each other. They both have a negative effect on 
HIV progression as measured by increase in viral load amounts. The increase in viral load 
amount with negative and passive coping is happening at three times the rate of the increase by 
positive coping strategies. These results answer the hypothesis of whether there was a significant 
beneficial effect of coping type on HIV disease progression. 
Effect of outcome measurements. Consistent with the hypothesis, there was a 
significant main effect of outcome measurement, F (1, 163) = 9.658, MSe = 781.795, η2 = .056, 
p = .002. Follow up tests were conducted using LSD. The mean effect size for viral load studies 
(M = 18.45, SD = 30.58) were rated significantly higher than CD4 count (M = 7.04, SD = 27.69) 
in terms of effect sizes. This indicates a stronger association between the coping variables and 
disease progression, in the studies that used viral load as the outcome variable than studies that 
utilized CD4.  
Effect of coping type. Contrary to the hypothesis, there was a non-significant effect of 
coping type, F (2, 163) = .464, MSe = 781.795, η2 = .006, p = .630. The non-significant effect of 
coping type means that one cannot say which coping type has the strongest effect on HIV 
progression over both outcome variables. This non-significant finding is not a large issue, as the 
interaction between coping type and outcome measurement, which was significant. The 
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significant interaction answers the hypotheses of whether coping has an effect on disease 
progression and which type has the largest beneficial effect. 
Potential moderating variables. A 2 x 3 ANCOVA was performed on the coping data 
set to test the nature of the interaction between outcome measurements (CD4 versus viral load) 
and coping types (positive, passive, and negative coping) while controlling for the covariates of 
age, sex, and transmission type. A correlation matrix was created to see the correlations between 
the covariates and the weighted effect size. Significant correlations were found between the 
weighted effect size and the covariates age (r = 0.246, p = 0.001), transmission type (r =-0.237, p 
= 0.002), and sex (r = -0.178, p = 0.021). A 2 x 3 ANCOVA was used as a follow up to look at 
the interaction between outcome measurements on the coping types while controlling for the 
covariates of age, sex, and transmission type. 
In the initial ANOVA there was not a significant main effect of coping type F (2, 163) = 
.464, MSe = 781.795, η2 = .006, p = .630. After controlling for the set of covariates in the 
ANCOVA the type of coping remained insignificant, F (2, 160) = .748, MSe = 716.171, p = .475. 
This means that the difference in mean effect size between the three types of coping was still not 
significantly different even when controlling for the covariates. Although, it should be noted that 
after controlling for the set of three covariates the significance of the difference between the 
coping types did improve considerably. The covariate age (p = .011) was the only significant 
covariate of the three, thus it was the only one accounting for a significant variance in the 
analysis as opposed to sex (p = .218) and transmission type (p = .290). 
 After controlling for sex, transmission type, and age there still was a significant main 
interaction of outcome and coping type F (2,160) = 4.333, MSe = 716.171, p = 0.15. CD4 
negative coping effect sizes (estimated marginal means = -1.778, SE = 5.166) were significantly 
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less than CD4 passive coping (estimated marginal means = 6.069, SE = 5.383) and CD4 positive 
coping (estimated marginal means = 10.291, SE = 3.037). This was a similar finding to the 
results mentioned above before controlling for the set of covariates. It means that both positive 
and passive coping improve disease progression by an increase in CD4 cell counts while 
negative coping has a detrimental effect on progression.  
There was a significant main effect of outcome measurement F (1, 160) = 9.827, MSe = 
716.171, p = .002. Mean effect sizes of viral load (estimated marginal means = 24.179, SE = 
5.491) were significantly higher than that of CD4 effect sizes (estimated marginal means = 4.68, 
SE =2.683).  This indicates a stronger association between the coping variables and progression, 
in the studies that used viral load as the outcome variable than studies that utilized CD4. 
Sensitivity analyses. Tests of homogeneity were performed on the coping data set. The 
calculated Q from both the CD4 and viral load effect size groups was larger than critical value 
for Chi-Square (Table 4). Thus, the null hypothesis of homogeneity was retained. This means 
that variability across effect sizes exceed what would be expected based on sampling error. 
Heterogeneous distribution analysis was used as a follow up test in order to analyze the excess 
between study effect size variability. It assumed that the variability in this data set were random 
and fit a random effects model.  Among the CD4 set of effect sizes in the personality data set, the 
Qb (24.85) and Qw (574.35) were both greater than critical Chi-square values, thus a random 
effects model was used. The random effects model assumed that the variability between effect 
sizes was due to sampling error in the individual studies and variability in a true population’s 
effects.  Among the viral load set of effects, the Qb (22.80) and Qw (24.85) were also greater 
than the critical Chi-square values. Thus a random effects model was also performed on the viral 
load groups. 
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Lastly, sensitivity analyses were performed on the data set to analyze the publication 
biases inherent in meta-analyses. The fail-safe N for the coping data set was calculated to be 
2,970 additional studies must be found in order to increase the p value for this data set above 
0.05. This large fail-safe N number means that there were not any power issues and this is 
considered a strong data set that it unlikely to have publication bias issues or Type I errors. The 
Egger’s funnel plot is as a visual plot of publication bias for the data set. The funnel plot for the 
coping data set can be seen in Appendix B. The funnel plot can be interpreted as a well behaved 
data set. The bottom of the plot is made up of the studies with smaller sample sizes and spread 
evenly on both sides of the average effect size. The larger N studies tend towards the average. 
Although this plot is defined as well behaved it does not appear perfectly symmetrical. There is 
some variance in the relationship extending beyond the positive and negative three standard 
deviation range. Although it remains overall pretty symmetrical this means there may be some 
publication bias affecting the data set and coping findings. This may be influencing the non-
significant finding of coping type in the meta-analysis data set.  
Discussion 
Summary 
 This meta-analysis sought to discover the relationship between social support, personality 
type, and coping style on HIV severity as assessed by viral load and CD4 cell counts. This study 
arises from the issue of purely biomedical treatment modalities for people living with 
HIV/AIDS. The idea of making a complementary more effective and individually designed 
treatment that incorporates mental health care leads to the question of which psychosocial factors 
have the greatest impact on HIV progression, the framework for this study.  
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Consistent with the hypothesis, social support was found to significantly effect HIV 
progression. This finding supports the hypothesis that there would be a significant relationship 
between the social support types (structural support and functional support) and the outcome 
variables (CD4 and viral load). In further support of the hypothesis, both functional and 
structural social support had a beneficial relationship with HIV progression, as evidenced by 
lower viral load amounts and higher CD4 cell counts. However, inconsistent with the hypothesis 
the relationship between structural support and the outcome variables was significantly stronger 
than the relationship of functional support. This finding may be caused in part by the potential 
issue of correlation between the two types of social support. Structural support analyzes the 
degree of integration of an individual and size of network while functional support analyzes the 
function of the network. Potentially, there may be a threshold with one needing a high amount of 
structural support in order for functional support to work properly. Thus, the finding of a larger 
significant relationship between structural support than hypothesized with functional support. 
Overall, social support had a significant effect on slowing HIV progression over time. 
Consistent with the hypothesis, coping was found to significantly effect HIV progression. 
This finding supports the hypothesis that there would be a significant relationship between the 
coping types (positive coping, passive coping, and negative coping) and the outcome variables 
(CD4 and viral load).  Partially contrary to the hypothesis, that predicted positive and negative 
coping to have the strongest effect on disease progression, the largest effect on progression was 
seen with positive coping and passive coping. A non-significant difference was found between 
the mean effect sizes of the three coping types analyzed without taking into account the outcome 
measurement type. However, when solely analyzing the studies that utilized CD4 count as the 
outcome measurement, there was a significant difference between the three different coping 
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types. Consistent with the hypothesis, positive coping has the strongest protective benefit on 
CD4 counts, such that as an individual increases in their positive coping behaviors CD4 counts 
increase. Passive coping similarly has a strong protective benefit on CD4 counts. Consistent with 
the hypothesis, negative coping styles have a detrimental effect on CD4 counts, such that as an 
individual increases in their negative coping techniques their CD4 decreases. Within the viral 
load measurements there is not a significant difference between all three coping types. However 
consistent with the hypothesis, a significant difference exists between positive coping and the 
other two types (passive and negative coping). Contrary to the hypothesis, there is not a 
significant difference between passive and negative coping in terms of viral load, as seen in the 
CD4 outcome measurements. Individuals who engage in passive or negative coping types 
experience three times increase in viral load than those who engage in positive coping 
techniques. This discrepancy between the significance of viral load and CD4 may be due to the 
fact that viral load is not as strong and consistent of a predictor as CD4 (Chida et al., 2009). 
Furthermore, it is highly correlated with the covariates adherence and ARV usage, which could 
further suppress the significance of the data. 
Contrary to the hypothesis, an overall non-significant finding was found between 
personality and HIV progression in this meta-analysis across both outcome measurements. This 
indicates that personality type has a weak effect on HIV disease progression. This finding is 
contrary to the hypothesis that there would be a significant association between the outcome 
variables and personality type (neuroticism, extraversion, openness to experience, agreeableness, 
and conscientiousness). As hypothesized, the association between CD4 count and personality 
type was stronger than the association between viral load and personality type. This overall non-
significant finding between personality and progression indicates that across all the personality 
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types there is a weak association. However, on the individual type level some of the personality 
types were significantly associated with progression that can be interpreted as trends in the 
personality data set. This was seen with the traits: extraversion, conscientiousness, and openness 
to experience. As the level of these traits increased, slower disease progression occurred as 
measured by lower viral load and CD4 cell counts.   
Consistent with the hypothesis, among the studies that have CD4 count as the outcome 
variable, the strongest effect on progression was with openness to experience followed by 
agreeableness, conscientiousness, extraversion, and neuroticism in order of effect strength.  
These findings were slightly different than the hypothesized order of relationship strength 
between outcome and personality type. It was hypothesized that conscientiousness, 
agreeableness, and extraversion would all have the strongest protective effect on HIV 
progression as opposed to the findings of openness, agreeableness, and conscientiousness. There 
was a significant difference between extraversion and the openness, agreeableness, and 
conscientiousness types. Contrary to the hypothesis, as extraversion increased CD4 counts 
decreased. This finding is not seen in the majority of research. Extraversion has been show to 
have a protective relationship against negative health outcomes, although this is seen to varying 
degrees of significance (Williams et al., 2004). Further analysis of the different facets of 
extraversion should be researched in the future in order to understand the complete relationship 
between extraversion and CD4 count measurement of HIV progression. The predicted positive 
protective relationship that openness, agreeableness, and conscientious would increase as CD4 
counts increase was found.  
Consistent with the hypothesis, among the studies that have viral load as the outcome 
variable, the strongest significant individual trait effect on disease progression was with 
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conscientiousness followed by extraversion, openness, neuroticism, and agreeableness in order 
of strength of the relationship. This indicates which personality types cause the largest increase 
or decrease on viral load amounts. It was predicted that conscientiousness, agreeableness, and 
extraversion would have the largest protective effects on HIV progression. Conscientiousness, 
extraversion, and openness all have a negative relationship with progression, such that as 
individuals score higher on these traits they experience a decrease in viral load amounts. For 
agreeableness and neuroticism there was a positive relationship, such that as individuals score 
higher on these traits they experience an increase in viral load amounts. The hypothesized 
protective relationship of conscientiousness and extraversion was seen in the viral load data. 
However, the strong relationship between openness was not predicted. In the literature review 
there was a paucity of studies that analyzed the association of openness and HIV severity and 
thus the hypothesis was based on studies of other autoimmune diseases generally. Perhaps, the 
specific nature of HIV differs from general autoimmune diseases thus making openness more 
important within the HIV context. 
It is important to note that the personality data within the meta-analysis was the only 
category that did not have significant overall findings. This may be attributed to the often-weak 
nature of personality as a measure of protective health in the disease context. Potentially, using a 
predictive linear regression model the findings of personality may be effective in determining 
significance of other proven health benefits such social support. Personality may operate as a 
mediator variable between coping and social support type. An individual with a certain 
personality type may be more likely to perform protective healthy coping types and social 
support thus overall improving their CD4 counts. 
Limitations 
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 There are many limitations inherent to meta-analysis methods that must be taken into 
consideration when interpreting the findings. The two main types of limitations that must be 
analyzed are the Egger’s unweighted regression asymmetry test and the overall publication 
biases. In funnel plots that do not resemble an asymmetrical funnel shape this represents a non-
symmetrical relationship between effect size and sample size on the individual study level. This 
asymmetry can indicate a publication bias in the complete data set meaning that study authors 
are more likely to submit their studies if they had positive significant results than either null, 
non-significant, or negative results. This issue is seen to a small degree among the plots for 
coping and social support. The personality data set indicates that larger publication bias issues 
exist. This may be the due to the fact that the NEO-PR is a more costly test to administer than 
many of the measurements used in the two other data sets which impacts the results to be more 
likely be positive due to the positive publication bias effect. Although, it is important to note that 
Egger’s plots are liberal visual signifiers of potential symmetry issues. It is also important to note 
along side Egger’s plots the fail-safe number, which explains how many non-significant studies 
must exist to negate the significance of the findings. For each of the data sets the fail-safe 
number is very high, thus making it unlikely that this would affect the findings. 
The subgroup analyses and Egger’s funnel plot was done to examine the effect of sample 
sizes on findings. Overall, the analysis for social support did not show a stronger relationship in 
the studies with larger sample sizes. Normally, studies with larger sample sizes have stronger 
relationships because of increased power (Lipsey & Wilson, 2001).  However, in the personality 
and coping data sets this deviation may be the cause of some non-significant findings in the 
analysis. If the correlation between larger sample sizes and stronger relations were found, then in 
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those two data sets there would be larger effect sizes. Rather in these two data sets there were 
smaller thus weaker effect sizes.  
Future Implications 
 Despite the limitations and biases seen in this meta-analysis, the findings are valuable for 
improving HIV/AIDS treatment in a non-clinical way on the individual level. They could serve 
as complementary to an ARV regimen as things an individual could incorporate into their 
treatment. The results indicate that a psychological component should be seen as a necessary 
complement to medical interventions. Based on these findings, a potential community health 
program could be created in order to emphasize the protective benefits of social support. This 
model would emphasize the different components of functional support in an effort to increase 
positive interactions with a larger network. This then would be paired with mental health 
workshops for individuals newly diagnosed with HIV in order to emphasize the importance of 
positive coping strategies especially in regards to their health. Obviously, these programs would 
be difficult to enact on a global level with the large amount of people living with HIV/AIDS. 
However, a community mental health program tied to the ARV distribution timeline could easily 
be created as a more efficient and potentially doable program. The findings suggest that further 
research on the predictive validity of a combined model of psychosocial factors to decrease HIV 
severity could be the next step. The significant findings of social support and coping type can be 
effectively used in improving customizable individual treatment plans for people living with 
HIV/AIDS. The findings from this meta-analysis could be invaluable in the creation of a global 
complementary medical and mental health program that reduces HIV severity and slows disease 
progression.  
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Appendix A 
 
Meta-Analysis Coping Studies  
# 
First 
Author Year N 
Adverse psychosocial 
factor (measurement) Covariates Outcome  
Quality 
Score 
(0-4) 
Effect 
Size (r) 
1a Ironson, G. 2005 
16
0 Negative Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sex CD4 3 0.188 
1b Ironson, G. 2005 
16
0 Negative Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sex Viral Load 3 0.174 
2 Vassend, O. 2007 
10
4 
Negative Coping 
(WOC/EPQ) Ag, SES CD4 2 0.097 
3 Cole, S. 1996 80 
Passive Coping (Diagnostic 
Interview) Ag, ARV CD4 2 0.216 
4 Patterson, T. 1996 
41
4 Negative Coping (WOC) Ag, Rc, SES CD4 2 0 
5 Mulder, C. 1995 51 Negative Coping (HCL) Ag, SES, ARV CD4 2 0 
6a McGuffey, L 2001 55 
Positive Coping 
(IWORSHIP) 
Ag, Rc, Ad, 
SES, Sx, ARV CD4 2 0.31 
6b McGuffey, L 2001 55 
Positive Coping 
(IWORSHIP) 
Ag, Rc, Ad, 
SES, Sx, ARV CD4 2 -0.29 
6c McGuffey, L 2001 55 
Positive Coping 
(IWORSHIP) 
Ag, Rc, Ad, 
SES, Sx, ARV Viral Load 2 -0.1 
6d McGuffey, L 2001 55 
Positive Coping 
(IWORSHIP) 
Ag, Rc, Ad, 
SES, Sx, ARV Viral Load 2 -0.09 
7a Milam, J 2006 
41
2 Positive Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or CD4 3 0.07 
7b Milam, J 2006 
41
2 Positive Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or CD4 3 0.04 
7c Milam, J. 2006 
41
2 Positive Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or CD4 3 0.03 
7d Milam, J 2006 
41
2 Negative Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or CD4 3 -0.04 
7e Milam, J 2006 
41
2 Negative Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or CD4 3 -0.07 
7f Milam, J 2006 
41
2 Positive Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or Viral Load 3 -0.14 
7g Milam, J 2006 
41
2 Positive Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or Viral Load 3 -0.06 
7h Milam, J. 2006 
41
2 Positive Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or Viral Load 3 -0.1 
7i Milam, J 2006 
41
2 Negative Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or Viral Load 3 0.13 
7j Milam, J 2006 
41
2 Negative Coping (LOT-R) 
Ag, Rc, Ad, 
SES, ARV, Sex, 
Or Viral Load 3 0.16 
8a Cole, S. 2003 54 Negative Coping (PANAS) 
Ag, RC, SES, 
Or Viral Load 2 0.75 
8b Cole, S. 2003 54 Negative Coping (PANAS) 
Ag, RC, SES, 
Or Viral Load 2 -0.18 
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9a 
Eisenberger, 
N. 2003 61 Positive Coping (LIWC) 
Ag, Rc, SES,Sx, 
Or CD4 1 -0.01 
9b 
Eisenberger, 
N. 2003 61 Passive Coping (LIWC) 
Ag, Rc, SES,Sx, 
Or CD4 1 -0.34 
9c 
Eisenberger, 
N. 2003 61 Negative Coping (LIWC) 
Ag, Rc, SES,Sx, 
Or CD4 1 -0.12 
10a 
Tomakowsk
y, J. 2001 78 Positive Coping (LOT) 
Ag, Ys, Ad, 
SES, ARV, Sx, 
Or CD4 2 -0.05 
10b 
Tomakowsk
y, J. 2001 78 Negative Coping (PANAS) 
Ag, Rc, Ys, Ad, 
SES, ARV, Sx,  
Or CD4 2 -0.14 
11 Thornton, S. 2000 
14
7 Positive Coping (COPE) Ag, SES, ARV CD4 3 0 
12 Vassend, O. 1997 
10
7 Passive Coping (WOC) Ag, SES CD4 2 0.097 
13a Mulder, C. 1995 51 Positive Coping (HCL) Ag, SES, ARV CD4 3 0.166 
13b Mulder, C. 1995 51 Passive Coping (HCL) Ag, SES, ARV CD4 3 0 
14a Woods, T. 1999 
10
6 Positive Coping (COPE) 
Ag, Rc, ARV, 
Or CD4 2 0.139 
14b Woods, T. 1999 
10
6 Positive Coping (COPE) 
Ag, Rc, ARV, 
Or CD4 2 0.19 
15 
Lutgendorf, 
S. 1997 22 Positive Coping  (COPE) Ag, Rc CD4 4 -0.11 
16 Solano,L. 2001 42 Positive Coping (RA) Ag, TT, Sx, Or CD4 2 0.28 
17a Greeson, J. 2008 
20
0 Passive Coping (IES) 
Ag, Rc, Ys, 
ARV, Sx CD4 3 -0.18 
17b Greeson, J. 2008 
20
0 Passive Coping (IES) 
Ag, Rc, Ys, 
ARV, Sx Viral Load 3 0.22 
18a Mulder, C. 1995 18 Positive Coping (COPE) Rc, SES, Or CD4 3 0.007 
18a Mulder, C. 1995 18 Passive Coping (COPE)  Rc, SES, Or CD4 3 0.52 
19a Solano, L. 2002 
20
0 
Positive Coping 
(Temoshok) 
Ag, TT, Ys, Sx, 
Or CD4 3 0.201 
19b Solano, L. 2002 
20
0 
Passive Coping 
(Temoshok) 
Ag, TT, Ys, Sx, 
Or CD4 3 0.271 
20a Ramer, L. 2006 
42
0 Positive Coping (QOL) 
Ag, Rc, SES, 
Sx, Or CD4 3 0.152 
20b Ramer, L. 2006 
42
0 Positive Coping (STS) 
Ag, Rc, SES, 
Sx, Or CD4 3 -0.044 
21 Reed,G. 1999 72 Negative Coping (NHAPS) Ag, Rc, Or CD4 4 0.024 
22a 
Segerstrom, 
S. 1996 82 Positive Coping (NHAPS) Ag, Rc, Or CD4 4 0.122 
22b 
Segerstrom, 
S. 1996 82 Positive Coping (NHAPS) Ag, Rc, Or CD4 4 0.037 
23a Bower, J. 1998 40 
Positive Coping (Cognitive 
Processing) Ag,ARV, Or CD4 3 -0.04 
23b Bower, J. 1998 40 
Positive Coping (Discovery 
of Meaning) Ag,ARV, Or CD4 3 -0.015 
24a Vassend, O. 1998 62 Positive Coping (WCCL) Ag, Ys, Or CD4 3 -0.286 
24b Vassend, O. 1998 62 Positive Coping (WCCL) Ag, Ys, Or CD4 3 -0.21 
24c Vassend, O. 1998 62 Positive Coping (WCCL) Ag, Ys, Or CD4 3 -0.316 
24d Vassend, O. 1998 62 Positive Coping (WCCL) Ag, Ys, Or CD4 3 -0.341 
24e Vassend, O. 1998 62 Positive Coping (WCCL) Ag, Ys, Or CD4 3 -0.07 
24f Vassend, O. 1998 62 Negative Coping (WCCL) Ag, Ys, Or CD4 3 0.027 
24g Vassend, O. 1998 62 Negative Coping (WCCL) Ag, Ys, Or CD4 3 -0.332 
25a O'Cleirigh, 2003 41 Positive Coping (Depth of Ag, Rc, TT, Ys, CD4 3 0.495 
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C. Processing) Ad, SES, ARV, 
Sx, Or 
25b 
O'Cleirigh, 
C. 2003 94 
Positive Coping (Depth of 
Processing) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 3 0.125 
25c 
O'Cleirigh, 
C. 2003 41 
Positive Coping (Positive 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 3 0.495 
25d 
O'Cleirigh, 
C. 2003 94 
Positive Coping (Positive 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 3 0.171 
25e 
O'Cleirigh, 
C. 2003 41 
Negative Coping (Negative 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 3 0.099 
25f 
O'Cleirigh, 
C. 2003 94 
Negative Coping (Negative 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 3 0.001 
25g 
O'Cleirigh, 
C. 2003 41 
Positive Coping (Depth of 
Processing) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 3 0.224 
25h 
O'Cleirigh, 
C. 2003 94 
Positive Coping (Depth of 
Processing) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 3 0.077 
25i 
O'Cleirigh, 
C. 2003 41 
Positive Coping (Positive 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 3 0.469 
25j 
O'Cleirigh, 
C. 2003 94 
Positive Coping (Positive 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 3 0.315 
25k 
O'Cleirigh, 
C. 2003 41 
Negative Coping (Negative 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 3 0.056 
25l 
O'Cleirigh, 
C. 2003 94 
Negative Coping (negative 
Emotional Expression) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 3 0.036 
26a Ashton, E. 2005 65 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx, 
Or CD4 4 -0.07 
26b Ashton, E. 2005 65 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx, 
Or CD4 4 -0.07 
26c Ashton, E. 2005 65 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx, 
Or CD4 4 0.01 
26d Ashton, E. 2005 65 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx, 
Or CD4 4 0.01 
26e Ashton, E. 2005 65 Negative Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx, 
Or CD4 4 -0.08 
26f Ashton, E. 2005 65 Negative Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx, 
Or CD4 4 -0.05 
27 Leserman, J. 2000 82 Passive Coping (COPE) 
Ag, Rc, Ys, Ad, 
ARV, Or CD4 4 0.257 
28a 
Temoshok, 
L. 2008 
27
3 
Positive Coping 
(Temoshok) Ag, Rc, Sx CD4 4 -0.134 
28b 
Temoshok, 
L. 2008 
27
3 
Negative Coping 
(Temoshok) Ag, Rc, Sx CD4 4 -0.152 
 28c 
Temoshok, 
L. 2008 
27
3 
Positive Coping 
(Temoshok) Ag, Rc, Sx Viral Load 4 0.165 
28d Temoshok, 2008 27 Negative Coping Ag, Rc, Sx Viral Load 4 0.179 
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L. 3 (Temoshok) 
29 Mulder, C. 1999 
18
1 Passive Coping (UCL) Ag, Ys, SES, Or CD4 4 -0.15 
30a Ironson, G. 2006 
10
0 Positive Coping (LOT) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 4 0.158 
30b Ironson, G. 2006 
10
0 
Positive Coping (Proactive 
Coping) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 4 0.258 
30c Ironson, G. 2006 
10
0 
Positive Coping 
(Spirituality) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 4 0.301 
30d Ironson, G. 2006 
10
0 Passive Coping (COPE) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 4 0.2 
30e Ironson, G. 2006 
10
0 Positive Coping (LOT) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 4 0.153 
30f Ironson, G. 2006 
10
0 
Positive Coping (Proactive 
Coping) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 4 0.045 
30g Ironson, G. 2006 
10
0 Positive Coping (COPE) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 4 0.293 
30h Ironson, G. 2006 
10
0 Passive Coping (LOT) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or Viral Load 4 0.243 
31 
O'Connell-
Edwar 2008 99 Positive Coping (LOT) Ag, Rc, SES  CD4 4 -0.119 
32a Dalmida, G. 2009 
12
9 Positive Coping (SWB) 
Ag, Rc, Ad, 
ARV CD4 4 0.19 
32b 
Dalmida, 
SG. 2009 
12
9 Positive Coping (SWB) 
Ag, Rc, Ad, 
ARV CD4 4 0.19 
32c Dalmida, G. 2009 
12
9 Positive Coping (SWB) 
Ag, Rc, Ad, 
ARV CD4 4 0.128 
32d 
Dalmida, 
SG. 2009 
12
9 Positive Coping (SWB) 
Ag, Rc, Ad, 
ARV CD4 4 0.128 
32e Dalmida, G. 2009 
12
9 Positive Coping (SWB) 
Ag, Rc, Ad, 
ARV CD4 4 0.174 
32f 
Dalmida, 
SG. 2009 
12
9 Positive Coping (SWB) 
Ag, Rc, Ad, 
ARV CD4 4 0.174 
33a Ironson, G. 2011 
10
1 Positive Coping (COPE) 
Ag, Rc, Ad, 
ARV, Sex CD4 4 0.26 
33b Ironson, G. 2011 
10
1 Positive Coping (GIS) 
Ag, Rc, Ad, 
ARV, Sex CD4 4 0.215 
33c Ironson, G. 2011 
10
1 Positive Coping (LOT) 
Ag, Rc, Ad, 
ARV, Sex CD4 4 0.16 
33d Ironson, G. 2011 
10
1 Passive Coping (COPE) 
Ag, Rc, Ad, 
ARV, Sex CD4 4 0.2 
33e Ironson, G. 2011 
10
1 Negative Coping (GIS) 
Ag, Rc, Ad, 
ARV, Sex CD4 4 -0.443 
33f Ironson, G. 2011 
10
1 Positive Coping (COPE) 
Ag, Rc, Ad, 
ARV, Sex Viral Load 4 0.05 
33g Ironson, G. 2011 
10
1 Positive Coping (GIS) 
Ag, Rc, Ad, 
ARV, Sex Viral Load 4 -0.209 
33h Ironson, G. 2011 
10
1 Positive Coping (LOT) 
Ag, Rc, Ad, 
ARV, Sex Viral Load 4 0.15 
33i Ironson, G. 2011 
10
1 Passive Coping (COPE) 
Ag, Rc, Ad, 
ARV, Sex Viral Load 4 0.24 
33j Ironson, G. 2011 
10
1 Negative Coping (GIS) 
Ag, Rc, Ad, 
ARV, Sex Viral Load 4 0.309 
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34a Trevino, K. 2007 
32
9 Positive Coping (FACIT) Ag, Ys, Sx,Or CD4 3 -0.04 
34b Trevino, K. 2007 
32
9 Positive Coping (PUREL) Ag, Ys, Sx,Or CD4 3 -0.027 
34c Trevino, K. 2007 
32
9 Positive Coping (FACIT) Ag, Ys, Sx,Or Viral Load 3 0.12 
34d Trevino, K. 2007 
32
9 Positive Coping (PUREL) Ag, Ys, Sx,Or Viral Load 3 0.089 
35a Miller, G. 1997 
20
5 Negative Coping (POMS) 
Ag, Rc, Ad, 
ARV, Or CD4 4 -0.03 
35b Miller, G. 1997 
20
5 Negative Coping (POMS) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.12 
35c Miller, G. 1997 
20
5 Negative Coping (POMS) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.09 
36a Ironson, G. 2005 
16
0 Positive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx CD4 3 0.254 
36b Ironson, G. 2005 
17
7 Positive Coping (LOT) 
Ag, Rc, Ad, 
SES, ARV, Sx CD4 3 0.19 
36c Ironson, G. 2005 
16
0 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx CD4 3 -0.139 
36d Ironson, G. 2005 
16
0 Positive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx Viral Load 3 0.048 
36e Ironson, G. 2005 
17
7 Positive Coping (LOT) 
Ag, Rc, Ad, 
SES, ARV, Sx Viral Load 3 -0.001 
36f Ironson, G. 2005 
16
0 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx Viral Load 3 0.213 
36g Ironson, G. 2005 
16
0 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES, ARV, Sx Viral Load 3 0.167 
37a 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.368 
37b 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.534 
37c 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.673 
37d 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.243 
37e 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.913 
37f 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.072 
37g 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.097 
37h 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.501 
37i 
Oppenheime
r, M. 2008 78 Positive Coping (WOC) Rc, SES, Sx CD4 3 0.739 
37j 
Oppenheime
r, M. 2008 78 Negative Coping (WOC) Rc, SES, Sx CD4 3 0.439 
37k 
Oppenheime
r, M. 2008 78 Negative Coping (WOC) Rc, SES, Sx CD4 3 0.257 
37l 
Oppenheime
r, M. 2008 78 Negative Coping (WOC) Rc, SES, Sx CD4 3 0.026 
38a Vosvick, M. 2002 
14
1 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES< ARV, Sx, 
Or CD4 4 -0.13 
38b Vosvick, M. 2002 
14
1 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES< ARV, Sx, 
Or CD4 4 -0.15 
38c Vosvick, M. 2002 
14
1 Passive Coping (COPE) 
Ag, Rc, Ad, 
SES< ARV, Sx, 
Or CD4 4 -0.14 
38d Vosvick, M. 2002 14 Negative Coping (COPE) Ag, Rc, Ad, CD4 4 -0.05 
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1 SES< ARV, Sx, 
Or 
38e Vosvick, M. 2002 
14
1 Negative Coping (COPE) 
Ag, Rc, Ad, 
SES< ARV, Sx, 
Or CD4 4 0.12 
39 Devine, D. 1997 64 Positive Coping (LOT) Ag, SES CD4 4 -0.16 
40a Ball, J. 2002 99 Positive Coping (COPE) Ag, SES CD4 3 0.114 
40b Ball, J. 2002 99 Positive Coping (COPE) Ag, SES CD4 3 -0.005 
41a 
Bakke-
Friedland 1999 97 Positive Coping (IRM) Ag, Rc, SES, Or CD4 3 -0.197 
41b 
Bakke-
Friedland 1999 97 Positive Coping (IRM) Ag, Rc, SES, Or CD4 3 -0.023 
42a 
Koopman, 
C. 2000 
14
7 Passive Coping (COPE) 
Ag, Rc, Ys, 
SES, Sx, Or CD4 4 0.316 
42b 
Koopman, 
C. 2000 
14
7 Passive Coping (COPE) 
Ag, Rc, Ys, 
SES, Sx, Or CD4 4 0.285 
42c 
Koopman, 
C. 2000 
14
7 Negative Coping (COPE) 
Ag, Rc, Ys, 
SES, Sx, Or CD4 4 -0.021 
43 
Thomason, 
B. 1996 
10
0 Positive Coping (WOC) Ag, Rc, Ys, Sx CD4 3 -0.214 
44a Ironson, G. 2009 
14
7 
Positive Coping (Ironson-
Woods) 
Ag, Rc, Ys, 
SES, ARV, Sx CD4 4 0.198 
44b Ironson, G. 2009 
14
7 
Positive Coping (Ironson-
Woods) 
Ag, Rc, Ys, 
SES, ARV, Sx Viral Load 4 0.202 
45 Ickovics, J. 2006 
87
1 Positive Coping (POMS) 
Ag, Rc, Ad, 
SES, ARV, 
SES, Ad, Sx CD4 4 -0.18 
46a Thornton, S. 2000 
14
7 Positive Coping (COPE) Ag, SES, ARV CD4 3 0.269 
46b Thornton, S. 2000 
14
7 Positive Coping (COPE) Ag, SES, ARV CD4 3 0.162 
47a 
Krikorian, 
R. 1995 57 Positive Coping (WOC) Ag, Ys, Sx CD4 3 0.35 
47b 
Krikorian, 
R. 1995 56 Positive Coping (WOC) Ag, Ys, Sx CD4 3 0.535 
48a Anderson, E. 2000 98 Positive Coping (LOT) Ag, Rc, SES, Sx CD4 3 0.073 
48b Anderson, E. 2000 98 Positive Coping (PLT) Ag, Rc, SES, Sx CD4 3 0.026 
49a Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 0.16 
48b Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 0.12 
48c Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 0.13 
48d Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 0.03 
48e Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 0.12 
48f Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 -0.07 
48g Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 0.27 
48h Vassend, O. 1997 
10
4 Positive Coping (WCCL) Ag, Ys,Sx CD4 2 0.12 
48i Vassend, O. 1997 
10
4 Negative Coping (WCCL) Ag, Ys,Sx CD4 2 -0.11 
50a Grassi, L. 1999 73 Positive Coping (IBQ) 
Ag, TT, Ys, Sx, 
Or CD4 3 -0.3 
59b Grassi, L. 1999 73 Passive Coping (IBQ) 
Ag, TT, Ys, Sx, 
Or CD4 3 -0.27 
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51 Ullrich, P. 2003 73 Passive Coping (CT) Ag, SES, Or CD4 3 0.34 
52 Hobbs, M. 2010 82 Positive Coping (SWB) 
Ag, Rc, Ad, 
SES, ARV, Or CD4 4 0.139 
53 Rice, E. 2009 
19
6 Positive Coping (DOS) 
Ag, Rc, Ys, 
SES, Sx CD4 3 0.233 
54 Biggar, H. 1999 
20
5 Positive Coping (LOT) Ag CD4 2 -0.14 
55 
Kalichman, 
S. 2002 
24
1 Positive Coping (PTA) 
Ag, Rc, Ys, 
SES, Sx, Or Viral Load 2 0.43 
 
Covariates: Ag = Age, Rc = Race, TT = Transmission Type, YS = Year Since Diagnosis, Ad = Adherence, ARV = Usage of 
ARV’s ,SES = socio-economic status, Sx = Sex, Or = Sexual Orientation  
 
 
 
Meta-Analysis Personality Studies  
# First Author Year N 
Adverse psychosocial 
factor (measurement) Covariates Outcome  
Quality 
Score (0-4) 
Effect 
Size (r ) 
1a Ironson, G. 2008 104 Neuroticism 
Ag, Rc, Ad, SES, 
ARV, Sx CD4 3 -0.028 
1b Ironson, G. 2008 104 Neuroticism 
Ag, Rc, Ad, SES, 
ARV, Sx Viral Load 3 0.001 
1c Ironson, G. 2008 104 Extraversion 
Ag, Rc, Ad, SES, 
ARV, Sx CD4 3 0.045 
1d Ironson, G. 2008 104 Extraversion 
Ag, Rc, Ad, SES, 
ARV, Sx Viral Load 3 -0.03 
1e Ironson, G. 2008 104 Openness 
Ag, Rc, Ad, SES, 
ARV, Sx CD4 3 0.053 
1f Ironson, G. 2008 104 Openness 
Ag, Rc, Ad, SES, 
ARV, Sx Viral Load 3 -0.025 
1g Ironson, G. 2008 104 Agreeableness 
Ag, Rc, Ad, SES, 
ARV, Sx CD4 3 0 
1h Ironson, G. 2008 104 Agreeableness 
Ag, Rc, Ad, SES, 
ARV, Sx Viral Load 3 0.009 
1i Ironson, G. 2008 104 Conscientiousness 
Ag, Rc, Ad, SES, 
ARV, Sx CD4 3 0.02 
1j Ironson, G. 2008 104 Conscientiousness 
Ag, Rc, Ad, SES, 
ARV, Sx Viral Load 3 0.015 
2 
Thornton, 
S. 2000 147 Neuroticism Ag, SES, ARV CD4 3 0 
3a 
O'Cleirigh, 
C. 2007 119 Conscientiousness 
Ag, Rc, Ad, SES, 
ARV, Sx, Or CD4 3 0.196 
3b 
O'Cleirigh, 
C. 2007 119 Conscientiousness 
Ag, Rc, Ad, SES, 
ARV, Sx, Or Viral Load 3 -0.213 
4 Lockenhoff 2009 112 Neuroticism Ag,Sx CD4 3 0.2 
5 
Johnson, 
M. 2007 258 Neuroticism 
Ag, Rc, Ad, SES, 
ARV , Sx  CD4 3 0.08 
6 
Thornton, 
S. 2000 147 Neuroticism Ag, SES, ARV CD4 3 0 
7 
Vassend, 
O. 1997 107 Neuroticism Ag, SES CD4 2 0.097 
8a Millner, V. 1998 76 Neuroticism Ag CD4 3 0.03 
8b Millner, V. 1998 76 Extraversion Ag CD4 3 0.114 
8c Millner, V. 1998 76 Openness Ag CD4 3 0.031 
8d Millner, V. 1998 76 Agreeableness Ag CD4 3 0.291 
8e Millner, V. 1998 76 Agreeableness Ag CD4 3 0.107 
8f Millner, V. 1998 76 Agreeableness Ag CD4 3 0.161 
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8g Millner, V. 1998 76 Agreeableness Ag CD4 3 0.328 
8h Millner, V. 1998 76 Agreeableness Ag CD4 3 0.121 
8i Millner, V. 1998 76 Agreeableness Ag CD4 3 0.154 
8j Millner, V. 1998 76 Agreeableness Ag CD4 3 0.227 
8k Millner, V. 1998 76 Conscientiousness Ag CD4 3 0.224 
8l Millner, V. 1998 76 Conscientiousness Ag CD4 3 0.02 
8m Millner, V. 1998 76 Conscientiousness Ag CD4 3 0.233 
8n Millner, V. 1998 76 Conscientiousness Ag CD4 3 0.04 
8o Millner, V. 1998 76 Conscientiousness Ag CD4 3 0.333 
8p Millner, V. 1998 76 Conscientiousness Ag CD4 3 0.05 
8q Millner, V. 1998 76 Extraversion Ag CD4 3 0.138 
8r Millner, V. 1998 76 Openness Ag CD4 3 0.188 
9a Ironson, G. 2005 56 Conscientiousness 
Ag, Rc, Ad, SES, 
ARV, Sex CD4 3 0.269 
9b Ironson, G. 2005 56 Conscientiousness 
Ag, Rc, Ad, SES, 
ARV, Sex Viral Load 3 -0.284 
10 
Bottonari, 
K. 2005 24 Neuroticism 
Ag, Rc, TT, SES, 
Sx, Or CD4 2 -0.131 
11a Erlen, J. 2011 211 Neuroticism Ag, Rc, Sx CD4 4 0.234 
11b Erlen, J. 2011 211 Extraversion Ag, Rc, Sx CD4 4 -0.306 
11c Erlen, J. 2011 211 Openness Ag, Rc, Sx CD4 4 0.26 
11d Erlen, J. 2011 211 Agreeableness Ag, Rc, Sx CD4 4 -0.07 
11e Erlen, J. 2011 211 Conscientiousness Ag, Rc, Sx CD4 4 -0.157 
12a 
Vassend, 
O. 2007 104 Neuroticism Ag, Ys, Sx CD4 2 0.15 
12b 
Vassend, 
O. 2007 104 Extraversion Ag, Ys, Sx CD4 2 -0.27 
13 Ullrich, P. 2003 73 Neuroticism Ag, SES, Or CD4 3 -0.072 
 
Covariates: Ag = Age, Rc = Race, TT = Transmission Type, YS = Year Since Diagnosis, Ad = Adherence, ARV = Usage of 
ARV’s, SES = socio-economic status, Sx = Sex, Or = Sexual Orientation  
 
Meta-Analysis Social Support Studies  
# First Author Year N Adverse psychosocial factor (measurement) Covariates Outcome  
Quality 
Score 
(0-4) 
Effect 
Size (r) 
1a Thornton, S. 2000 147 Functional Support (ISEL) Ag, SES, ARV CD4 3 0.269 
1b Thornton, S. 2000 147 Functional Support (ISEL) Ag, SES, ARV 
Viral 
Load 3 0.162 
2a Cole, S. 2003 54 Functional Support (SI) Ag, Rc, SES, Or CD4 3 0.57 
2b Cole, S. 2003 54 Functional Support (SI) 
Ag, Rc, SES, Or, 
ARV CD4 3 -0.61 
2c Cole, S. 2003 54 Structural Support (SI) Ag, Rc, SES, Or 
Viral 
Load 3 0.68 
2d Cole, S. 2003 54 Structural Support (SI) Ag, Rc, SES, Or 
Viral 
Load 3 0.75 
2e Cole, S. 2003 54 Structural Support (SI) Ag, Rc, SES, Or 
Viral 
Load 3 0.58 
3a 
Eisenberger, 
N. 2003 61 Structural Support (NSSQ) Ag, Rc, SES, Sx CD4 4 -0.17 
3b 
Eisenberger, 
N. 2003 61 Structural Support (NSSQ) Ag, Rc, SES, Sx CD4 4 -0.15 
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3c 
Eisenberger, 
N. 2003 61 Structural Support (NSSQ) Ag, Rc, SES, Sx CD4 4 -0.32 
3d 
Eisenberger, 
N. 2003 61 Structural Support (NSSQ) Ag, Rc, SES, Sx CD4 4 -0.13 
3e 
Eisenberger, 
N. 2003 61 Structural Support (NSSQ) Ag, Rc, SES, Sx CD4 4 -0.07 
4a Ironson, G. 2005 160 Functional Support (ESSI) 
Ag, Rc, Ad, 
SES, ARV, Sx CD4 3 0 
4b Ironson, G. 2005 160 Functional Support (ESSI) 
Ag, Rc, Ad, 
SES, ARV, Sx 
Viral 
Load 3 0 
5a Burgoyne, R 2005 65 
Functional Support 
(MOSSSS) ARV, Sx CD4 2 0.287 
5b Burgoyne, R 2005 65 
Functional Support 
(MOSSSS) ARV, Sx 
Viral 
Load 2 0.326 
6a Young, J. 2004 
373
6 Structural Support (PSP) 
Ag, Rc, SES, 
ARV, Sx CD4 3 0.038 
6b Young, J. 2004 
373
6 Structural Support (PSP) 
Ag, Rc, SES, 
ARV, Sx 
Viral 
Load 3 0.016 
7a Persson, L. 2002 64 Structural Support (PFC) Ag CD4 3 0.06 
7b Persson, L. 2002 64 Structural Support (PSP) Ag CD4 3 0.01 
8 Thornton, S. 2000 147 Functional Support (ISEL) Ag, SES, ARV CD4 3 0 
9 Patterson, T. 1996 414 Functional Support (SSQ) Ag, Rc, SES CD4 2 0 
10 Theorell,T. 1995 51 Functional Support (SNSQ) Ag, SES, Or CD4 2 0.575 
11a Igreja, I. 2000 39 Functional Support (ISEL) Ag, SES, Or CD4 3 -0.114 
11b Igreja, I. 2000 39 Functional Support (SSHI) Ag, SES, Or CD4 3 -0.13 
12a Hobbs, M. 2010 82 Functional Support (SSQ) Ag,Or CD4 4 0.044 
12b Hobbs, M. 2010 82 Functional Support (SSQ) Ag,Or CD4 4 0.045 
13 Leserman, J. 1999 82 Functional Support (SBSSQ) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.4 
14 Leserman, J. 2002 82 Functional Support (SBSSQ) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.227 
15 Solano, L. 2002 200 Functional Support (SSS) 
Ag, TT, Ys, Sx, 
Or CD4 3 0.217 
16 Vassend, O. 1998 62 Functional Support (WCCL) Ag, Ys, Or CD4 3 -0.175 
17 Ashton, E. 2005 65 Functional Support (SSI) 
Ag, Rc, Ad, 
SES, ARV, Sx, 
Or CD4 4 -0.08 
18 Leserman, J. 2000 82 Functional Support (BSSQ) 
Ag, Rc, Ys, Ad, 
ARV, Or CD4 4 0.217 
19a Strachan, E. 2007 373 Structural Support (KS) 
Ag, Rc, ARV, 
Sx, Or CD4 3 0.019 
19b Strachan, E. 2007 373 Structural Support (KS) 
Ag, Rc, ARV, 
Sx, Or CD4 3 0.041 
20 Ironson, G. 2006 100 Functional Support (ESSI) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 4 0.184 
21a Fekete, E. 2009 102 Functional Support (SSI) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 4 0.206 
21b Fekete, E. 2009 102 Functional Support (SSI) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or CD4 4 -0.179 
21c Fekete, E. 2009 102 Structural Support (SSI) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or 
Viral 
Load 4 -0.247 
21d Fekete, E. 2009 102 Structural Support (SSI) 
Ag, Rc, TT, Ys, 
Ad, SES, ARV, 
Sx, Or 
Viral 
Load 4 0.145 
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22a Miller, G. 1997 205 Structural Support (SSI) 
Ag, Rc, Ad, 
ARV, Or CD4 4 -0.12 
22b Miller, G. 1997 205 Structural Support (SSI) 
Ag, Rc, Ad, 
ARV, Or CD4 4 -0.03 
22c Miller, G. 1997 205 Structural Support (SSI) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.02 
22d Miller, G. 1997 205 Structural Support (SSI) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.1 
22e Miller, G. 1997 205 Structural Support (SSI) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.11 
22f Miller, G. 1997 205 Structural Support (SSI) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.09 
22g MIller, G. 1997 205 Structural Support (UCLAL) 
Ag, Rc, Ad, 
ARV, Or CD4 4 0.18 
23a Cohen, M. 2007 56 Functional Support (PES) 
Ag, TT, Ys, Ad, 
SES, ARV,Sx CD4 2 0.31 
23b Cohen, M. 2007 56 Functional Support (PES) 
Ag, TT, Ys, Ad, 
SES, ARV,Sx 
Viral 
Load 2 -0.3 
24a 
Oppenheimer, 
M. 2008 78 Structural Support (MSPSS) Rc, TT, SES, Sx CD4 3 0.681 
24b 
Oppenheimer, 
M. 2008 78 Structural Support (MSPSS) Rc, TT, SES, Sx CD4 3 0.023 
24c 
Oppenheimer, 
M. 2008 78 Structural Support (MSPSS) Rc, TT, SES, Sx CD4 3 0.201 
25a Robbins, M. 2003 48 Structural Support (SSQ) Ag, SES CD4 3 0.43 
25b Robbins, M. 2003 20 Structural Support (SSQ) Ag, SES CD4 3 0.016 
25c Robbins, M. 2003 20 Structural Support (SSQ) Ag, SES CD4 3 0.065 
25d Robbins, M. 2003 15 Structural Support (SFSR) Ag, SES CD4 3 0.038 
25e Robbins, M. 2003 20 Structural Support (SFSR) Ag, SES CD4 3 0.057 
25f Robbins, M. 2003 48 Functional Support (SSQ) Ag, SES CD4 3 0.255 
25g Robbins, M. 2003 26 Functional Support (SSQ) Ag, SES CD4 3 -0.016 
25h Robbins, M. 2003 12 Functional Support (SSQ) Ag, SES CD4 3 0.183 
26a LeGrand, S. 2010 435 Structural Support (IAS) Ag, Rc, SES CD4 4 0.1 
26b LeGrand, S. 2010 435 
Functional Support 
(MOSSSS) Ag, Rc, SES CD4 4 0.055 
26c LeGrand, S. 2010 435 
Functional Support 
(MOSSSS) Ag, Rc, SES CD4 4 0.01 
27a 
Bakke-
Friedland 1999 97 Functional Support (PSS) Ag, Rc, SES, Or CD4 3 -0.023 
27b 
Bakke-
Friedland 1999 97 Functional Support (PSS) Ag, Rc, SES, Or CD4 3 -0.148 
27c 
Bakke-
Friedland 1999 97 Functional Support (PSS) Ag, Rc, SES, Or CD4 3 0.338 
28a Tang, H. 2002 410 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 4 -0.06 
28b Tang, H. 2002 410 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 4 0.07 
28c Tang, H. 2002 410 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 4 0.093 
28d Tang, H. 2002 410 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 4 0.07 
29a Burgoyne,R. 2000 114 Structural Support (MOSSSS) Ag, SES, Sx CD4 3 0.296 
29b Burgoyne,R. 2000 114 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 3 -0.174 
29c Burgoyne,R. 2000 114 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 3 -0.089 
29d Burgoyne,R. 2000 114 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 3 -0.041 
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29e Burgoyne,R. 2000 114 
Functional Support 
(MOSSSS) Ag, SES, Sx CD4 3 -0.081 
30 Brashers, D. 2002 147 Structural Support (ACT) Rcm Ys, Sx, Or CD4 2 -0.012 
31 Koopman, C. 2000 147 Structural Support (SSI) 
Ag, Rc, Ys, SES, 
Sx, Or CD4 4 -0.102 
32a Igreja, I. 1997 88 Structural Support (SSHI) Ag, SES, Or CD4 4 -0.067 
32b Igreja, I. 1997 88 Structural Support (SSHI) Ag, SES, Or CD4 4 -0.112 
32c Igreja, I. 1997 88 Functional Support (SSHI) Ag, SES, Or CD4 4 -0.114 
32d Igreja, I. 1997 88 Functional Support (SSHI) Ag, SES, Or CD4 4 -0.13 
33 Burgoyne, R. 2005 34 
Functional Support 
(MOSSSS) ARV, Sx CD4 3 0.199 
34 Nair, K. 2009 120 Functional Support (MPSS) 
Ag, Rc, Ys, SES, 
ARV, Sx CD4 3 0.022 
35a Alemu, H. 2012 882 Functional Support (NSSQ) 
Ag, Ad, SES, 
ARV, Sx CD4 3 0.068 
35b Alemu, H. 2012 569 Functional Support (NSSQ) 
Ag, Ad, SES, 
ARV, Sx CD4 3 0.08 
36 Thomason, B. 1996 100 Functional Support (ISEL) Ag, Rc, Ys,Sx  CD4 3 0.101 
37 Vassend, O. 1997 104 Functional Support (WCCL) Ag, SES CD4 3 0 
38 Grassi, L. 1999 73 Structural Support (IBQ) 
Ag, TT, Ys, Sx, 
Or CD4 3 0.04 
39a Ullrich, P. 2003 73 Functional Support (SSQ) Ag, SES, Or CD4 3 0.225 
39b Ullrich, P. 2003 73 Functional Support (SCS) Ag, SES, Or CD4 3 -0.025 
40a 
DelaGarzaMe
rcer 2011 132 Functional Support (DAS) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 0.048 
40b 
DelaGarzaMe
rcer 2011 132 Functional Support (DAS) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 -0.07 
40c 
DelaGarzarM
erce 2011 132 Functional Support (CTS) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 -0.023 
40d 
DelaGarzaMe
rcer 2011 132 Functional Support (CTS) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 -0.108 
40e 
DelaGarzaMe
rcer 2011 132 Functional Support (SSQ) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 0.052 
40f 
DelaGarzaMe
rcer 2011 132 Functional Support (SSQ) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 0.2 
40g 
DelaGarzaMe
rcer 2011 132 Functional Support (SSQ) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 -0.243 
40h 
DelaGarzaMe
rcer 2011 132 Functional Support (SSQ) 
Ag, Rc, TT, Ad, 
SES, ARV, Or CD4 4 -0.01 
41 Lucero, T. 1999 69 Functional Support (ISEL) 
Ag, Rc, TT, 
ARV, Sx, Or CD4 4 -0.144 
42a Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx CD4 3 -0.23 
42b Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx CD4 3 -0.41 
42c Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx CD4 3 -0.27 
42d Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx CD4 3 -0.15 
42e Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx CD4 3 -0.3 
42f Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx CD4 3 -0.21 
42g Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx 
Viral 
Load 3 0.06 
42h Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx 
Viral 
Load 3 0.23 
42i Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx 
Viral 
Load 3 0.08 
42j Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx 
Viral 
Load 3 -0.09 
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42k Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx 
Viral 
Load 3 0.01 
42l Dutile, R. 2004 84 Functional Support (SPS) Ag, Sx 
Viral 
Load 3 0.04 
 
Covariates: Ag = Age, Rc = Race, TT = Transmission Type, YS = Year Since Diagnosis, Ad = Adherence, ARV = Usage of 
ARV’s ,SES = socio-economic status, Sx = Sex, Or = Sexual Orientation  
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Social Support Egger’s Funnel Plot
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Appendix C 
 
Coding Manual and Coding Forms for Meta-Analysis of Psychosocial Effects 
 
A. Study Level Coding Manual 
1. Bibliographical Reference 
a. Study ID Number 
b. Publication Year 
c. Quality Assessment Score (0-4) 
2. Sample Descriptors/Covariates 
a. Sample Size 
b. Cohort Nation 
c. Covariates (1 = Yes, 2 = No) 
i. Age 
ii. Race 
iii. Transmission Type 
iv. Years since Diagnosis 
v. Adherence to ARV’s 
vi. Usage of ARV’s 
vii. SES 
viii. Sex 
ix. Sexual Orientation 
3. Research Design Descriptors 
a. Follow Up Study (1 = Yes, 2 = No) 
b. Measure (Scale Used) 
c. Outcome Variable (1 = CD4, 2 = Viral Load) 
d. Independent Variable 
i. Social Support Data Set 
1. Structural Support = 1 
2. Functional Support = 2 
ii. Personality Data Set (1-5) 
1. Neuroticism = 1 
2. Extraversion = 2 
3. Openness to Experience = 3 
4. Agreeableness = 4 
5. Conscientiousness = 5 
iii. Coping Data Set (1-3) 
1. Positive Coping = 1 
2. Passive Coping = 2 
3. Negative Coping = 3 
 
B. Effect Size Level Coding Manual 
a. Effect Size (Pearson’s r) 
b. Weighted effect size 
c. Standard Error 
 
